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Abstract Parkinson’s disease (PD) is the second most com-
mon age-related neurodegenerative disorder typified by
tremor, rigidity, akinesia and postural instability due in part
to the loss of dopamine within the nigrostriatal system. The
pathologic features of this disorder include the loss of sub-
stantia nigra dopamine neurons and attendant striatal termi-
nals, the presence of large protein-rich neuronal inclusions
containing fibrillar α-synuclein and increased numbers of
activated microglia. Evidence suggests that both misfolded
α-synuclein and oxidative stress play an important role in
the pathogenesis of sporadic PD. Here we review evidence
that α-synuclein activates glia inducing inflammation and
that Nrf2-directed phase-II antioxidant enzymes play an
important role in PD. We also provide new evidence that
the expression of antioxidant enzymes regulated in part by
Nrf2 is increased in a mouse model of α-synuclein over-
expression. We show that misfolded α-synuclein directly
activates microglia inducing the production and release of
the proinflammatory cytokine, TNF-α, and increasing anti-
oxidant enzyme expression. Importantly, we demonstrate
that the precise structure of α-synuclein is important for
induction of this proinflammatory pathway. This complex
α-synuclein-directed glial response highlights the impor-
tance of protein misfolding, oxidative stress and inflamma-
tion in PD and represents a potential locus for the
development of novel therapeutics focused on induction of
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Introduction
In this invited paper we review existing literature, which
supports the concept that the Parkinson’s disease (PD) protein
α-synuclein plays a role in microglial activation and oxidative
stress. In addition, we provide new evidence that α-synuclein
overexpression induces an antioxidant response and that spe-
cific conformers ofα-synuclein cause complexmorphological
and functional microglial responses which involve both proin-
flammatory molecules and phase-II antioxidant enzymes. We
suggest that this multifaceted α-synuclein-directed glial re-
sponse represents a nexus between protein misfolding, oxida-
tive stress and inflammation providing a potential therapeutic
locus to halt the progression of PD.
PD and α-synuclein
PD is the most common age-related progressive neurode-
generative movement disorder affecting over 4 million peo-
ple worldwide a number that is expected to double by 2030
(Dorsey et al. 2007). One important locus of this disorder is
the nigrostriatal system where there is invariant loss of
substantia nigra pars compacta (SNpc) dopamine neurons
and striatal presynaptic terminals. A hallmark pathological
feature of PD is the presence of large cytoplasmic inclusions
of protein in the remaining dopamine neurons and neurites
(Rodrigues e Silva et al. 2010). These so-called Lewy bod-
ies and Lewy neurites are enriched in fibrillar α-synuclein
(Spillantini et al. 1997; Baba et al. 1998; Spillantini et al.
1998). Familial forms of this disorder have been identified
linking the gene that encodes α-synuclein, SNCA, as well as
a number of other genes to PD pathogenesis (reviewed in
(Lesage and Brice 2009; Hardy 2010; Martin et al. 2011)).
Later it was discovered that duplication or triplication of
SNCA causes an autosomal dominant form of PD where
disease severity is linked to gene dosage (Singleton et al.
2003; Chartier-Harlin et al. 2004; Singleton et al. 2004).
Importantly, genome wide association (GWA) studies im-
plicate SNCA with an increased risk of developing sporadic
PD, indicating that this protein plays a central role in both
sporadic and familial PD (Edwards et al. 2010). Further-
more, the fact that mutations in or overexpression of SNCA
cause PD indicates an α-synuclein toxic-gain-of-function
mechanism in this neurodegenerative disorder. Although
the exact mechanism by which α-synuclein leads to PD is
not completely understood there is evidence that the
propensity of this protein to misfold into toxic oligomers
promotes disease (reviewed in (El-Agnaf and Irvine 2000;
Cookson and van der Brug 2008)).
α-Synuclein is also involved in several other neurode-
generative disorders aptly named synucleinopathies (e.g.,
multiple system atrophy, diffuse Lewy body disease), which
have disparate initiating factors, multiple affected neuro-
transmitter systems and different cell loci of disease (i.e.,
dopamine neurons, cortical neurons, oligodendrocytes) sug-
gesting a multifaceted pathogenic mechanism. Thus far, in
some in vivo and in vitro models, α-synuclein overexpres-
sion, accumulation and/or oligomer formation is accompa-
nied by cell dysfunction or death (El-Agnaf et al. 1998;
Masliah et al. 2000; Lee et al. 2001; Kirik et al. 2002;
Danzer et al. 2007; Periquet et al. 2007; Desplats et al.
2009). In other overexpression models, α-synuclein does
not result in robust neuronal death, which may be a function
of the cell type expressing this protein and the amount of α-
synuclein expressed per cell (e.g., the formation of toxic
oligomers) (Matsuoka et al. 2001; Richfield et al. 2002;
Colapinto et al. 2006). The formation of various α-
synuclein protein conformers is promoted by molecular
crowding, dopamine modification, temperature, pH, metal
binding, pesticides and oxidative stress suggesting that
the cellular milieu determines how this protein misfolds
(Uversky et al. 2001a, c, b, d, 2002, 2007). There are a
large number of mechanistic studies suggesting that α-
synuclein’s toxic-gain-of-function is related to misfolding
of this protein and consequent effects on mitochondria,
proteasome and lysosome function (Hsu et al. 2000; Tanaka
et al. 2001; Elkon et al. 2002; Meredith et al. 2002; Giasson
and Lee 2003; Lindersson et al. 2004; Giorgi et al. 2006;
Martin et al. 2006; Devi et al. 2008; Emmanouilidou et al.
2010b). Impairment of these key organelles can lead to α-
synuclein-induced oxidative stress. In turn reactive oxygen
and nitrogen species incite α-synuclein aggregation putting
into motion a feed-forward cycle of synuclein-induced stress
(Hashimoto et al. 1999; Giasson et al. 2000; Paxinou et al.
2001; Ischiropoulos 2003). Antioxidant compounds inhibit
the formation of and destabilize preformed α-synuclein
fibrils in vitro (Ono and Yamada 2006) and have some
protective effects in models of PD (Trinh et al. 2008; Beal
2011; Martin et al. 2012; Martinez-Banaclocha 2012).
In the nigrostriatal system dopamine is a prominent
source of reactive oxygen species as this neurotransmitter
can auto-oxidize when not sequestered in vesicles. Antiox-
idant enzymes respond to this enhanced oxidative stress to
prevent neuronal damage. However when there is an excess
of free dopamine as might occur when presynaptic terminals
degenerate or vesicle recycling is impaired the amount of
oxidized dopamine and highly reactive dopamine quinone
intermediates increases leading to neurotoxicity (Asanuma
et al. 2003; Galvin 2006). Dopamine quinones are known to
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irreversibly modify proteins altering their normal function,
for example and relevant to our discussion, dopamine oxi-
datively modifies α-synuclein leading to the stabilization of
the toxic protofibrillar structure (i.e., oligomeric intermedi-
ates) (Conway et al. 2001). Dopamine modification of α-
synuclein also has cellular consequences as dopamine-
modified α-synuclein inhibits chaperone-mediated autoph-
agy, which would render dopamine neurons more vulnera-
ble to subsequent toxicants or stressors (Martinez-Vicente et
al. 2008). Therefore the nigrostriatal system may exhibit
enhanced vulnerability in PD because this region has high
levels of oxidative stress and is enriched in α-synuclein as
well as dopamine (Maguire-Zeiss et al. 2005; Mosharov et
al. 2009; Surmeier et al. 2010).
Microglial activation in PD
Microglia, the resident immune cells in the brain, continu-
ously monitor and react to their microenvironment. Engage-
ment of these cells with pathogen-associated molecular
patterns (PAMPs) such as bacterial- and viral-derived car-
bohydrates, nucleic acids and lipoproteins, results in activa-
tion mediated by pattern recognition receptors (PRRs) found
on the cell surface as well as on endosomal membranes (Hu
et al. 1996; Muzio et al. 2000; Lee and Lee 2002; Block et
al. 2007). Once these receptors are engaged by ligands (e.g.,
PAMPs), a cascade of cell signaling ensues which can result
in a classical activation pathway, including the production
and release of proinflammatory cytokines (e.g., tumor ne-
crosis factor-α (TNF-α) and interleukin-1β (IL-1β), nitric
oxide (NO) and superoxide. Alternatively, microglia can be
activated to produce anti-inflammatory cytokines (e.g.,
arginase-1 and transforming growth factor-β), demonstrat-
ing the ability of these cells to regulate inflammation, allow
for repair and promote homeostasis (Colton and Wilcock
2010). In addition to the typical PAMPs, sterile, non-
pathogen related endogenous molecules associated with dis-
ease, called “danger/damage-associated molecular patterns”
(DAMPs), are recognized by microglial PRRs (Halle et al.
2008; Chen and Nunez 2010; Duewell et al. 2010; Stewart
et al. 2010; Beraud et al. 2011; Beraud and Maguire-Zeiss
2012). DAMPs also cause microglia to produce and release
proinflammatory molecules. In fact, the ability of DAMPs to
activate microglia has been tied to a number of neurodegen-
erative disorders, including Alzheimer’s disease, where fi-
brillar Aβ activates microglia leading to phagocytosis of the
Aβ-containing plaque (Colton et al. 2000; Combs et al.
2001; El Khoury et al. 2003; Koenigsknecht and Landreth
2004; Jana et al. 2008). Likewise, α-synuclein, the PD
protein prone to aggregation, directly activates microglia
via a classical activation pathway and increases the expres-
sion of a subset of pattern recognition receptors (Zhang et al.
2005; Reynolds et al. 2008; Su et al. 2008; Theodore et al.
2008; Su et al. 2009; Lee et al. 2010a; Beraud et al. 2011;
Beraud and Maguire-Zeiss 2012).
Importantly, there is also evidence for increased micro-
glial activation in patients suffering from neurodegenerative
diseases. Patients diagnosed with PD demonstrate an over
six-fold increase in activated microglia compared to control
patients when imaged using positron emission tomography
(PET) and [11C](R)-PK11195, a ligand for the peripheral
type benzodiazepine receptor (PBR) (Ouchi et al. 2005;
Bartels and Leenders 2007; Ouchi et al. 2009; Bartels et
al. 2010). These receptors are found on mitochondria in
activated microglia and some neurons (Banati 2002) but
ligand binding is increased when glia are activated. Interest-
ingly, when PBR imaging was combined with PET for a
dopamine transporter ligand ([11C]CFT), Ouchi et al. found
an inverse correlation between midbrain [11C](R)-PK11195
and putamenal [11C]CFT and a positive correlation between
midbrain [11C](R)-PK11195 and motor severity (Ouchi et al.
2009). As PD progressed the striatal dopamine transporter
loss increased and the microglial activation encompassed
nearly the entire brain (Ouchi et al. 2009). Although these
in vivo imaging studies do not directly demonstrate that
microglia are activated (e.g., additional highly specific
microglial ligands are needed to confirm the PBR imaging
data) they do support the idea that glial activation is ongoing
in PD patients. Further evidence for an ongoing inflamma-
tory state in PD comes from studies demonstrating increased
levels of proinflammatory molecules (e.g., interleukins,
TNF-α, interferon gamma) in patient blood and cerebrospinal
fluid (CSF) as well as enhanced numbers of activated CD11b-
positive microglia in post-mortem PD brains at autopsy com-
pared with neurologically normal controls (McGeer et al.
1988; Barcia et al. 2004; El-Agnaf et al. 2006; Bartels and
Leenders 2007; Brodacki et al. 2008; Bartels et al. 2010; Shi et
al. 2011). Taken together, these studies suggest that persistent
inflammation and microglial activation are fundamental char-
acteristics of PD although the precise initiator, downstream
consequences and nature of this activation remain to be fully
determined.
α-Synuclein, microglial activation and oxidative stress
As mentioned above mounting evidence implicates mis-
folded α-synuclein in the initiation and progression of
microglial activation. For example, in transgenic mouse
model where expression is limited to tyrosine hydroxylase
containing neurons, overexpression of α-synuclein leads to
increased numbers of activated microglia in the SNpc in the
absence of dopamine neuron death (Su et al. 2008). Other α-
synuclein transgenic models also support a role for this
protein in neuronal dysfunction and degeneration, increased
oxidative stress and microglial activation (Feany and Bender
2000; He et al. 2001; Dawson et al. 2002; Theodore et al.
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2008; Kim et al. 2011a; Chesselet et al. 2012; Lastres-
Becker et al. 2012). In addition, non-human primate and
rodent studies employing neurotoxicants that target the
nigrostriatal pathway demonstrate increased numbers of ac-
tivated microglia prior to neuron death (Czlonkowska et al.
1996; Kohutnicka et al. 1998; Cicchetti et al. 2002; Depino
et al. 2003; Wu et al. 2005; Zhang et al. 2005; Gerhard et al.
2006; Kim and Joh 2006; Liu 2006; Qian et al. 2006b;
Sawada et al. 2006). Importantly, as mentioned above α-
synuclein has a direct effect on microglial activation in vitro
resulting in an overall increase in proinflammatory mole-
cules and oxidative stress (Zhang et al. 2005; Su et al. 2008;
Theodore et al. 2008; Su et al. 2009; Lee et al. 2010a;
Beraud et al. 2011; Beraud and Maguire-Zeiss 2012). Fur-
thermore, α-synuclein overexpression in animals and cell
culture models demonstrates that α-synuclein protein aggre-
gates can cause oxidative stress and increased cell vulnera-
bility (Hsu et al. 2000; Parihar et al. 2008, 2009; Feng et al.
2010).
In PD patients, as detailed above, blood and CSF have
detectable levels of proinflammatory molecules. Likewise,
human studies support that α-synuclein is present in human
plasma (El-Agnaf et al. 2006) and CSF (Mollenhauer et al.
2010, 2011). Interestingly, Tokuda et al. showed that CSF
from PD patients had decreased levels of total α-synuclein
but increased amounts of α-synuclein oligomers (Tokuda et
al. 2010). α-Synuclein was also detected in the blood and
brains from subjects with SNCA triplication PD (Miller et al.
2004). The presence of α-synuclein in the CSF is not limited
to PD patients and is found in samples from patients with
other synucleinopathies like dementia with Lewy bodies and
Alzheimer’s disease (Noguchi-Shinohara et al. 2009). In
vitro studies confirm that α-synuclein is localized to cell
membranes, released from cells including neurons (Lee et
al. 2005; Su et al. 2008; Emmanouilidou et al. 2010a; Feng
et al. 2010; Jang et al. 2010) and taken up by surrounding
glia (Lee et al. 2010b). Taken together, human and cell
model studies suggest that α-synuclein is released from
cells where it would be available for recognition by innate
immune cells, promote activation and enhance oxidative
stress.
Oxidative stress emanating from the cellular response to
misfolded proteins, proteostatic dysfunction, is a common
feature of neurodegenerative diseases and the PD-
nigrostriatal pathway has increased levels of reactive oxy-
gen species (ROS) and is particularly vulnerable to oxida-
tive stress (Bossy-Wetzel et al. 2004; Surmeier et al. 2010).
One source of oxidative stress emanates from the SNpc dopa-
mine neurons themselves during autonomous pacemaking
(Guzman et al. 2010) but neuronal stress can also originate
from decreased cellular antioxidant responses as well as in-
creased oxidative stress from surrounding activated glia
(reviewed in (Miller et al. 2009)). For example, we have
demonstrated that α-synuclein-directed microglial activation
increases the production of NO (Beraud et al. 2011), which
could adversely affect the health of surrounding neurons.
The master regulator of the cellular antioxidant response
is the transcription factor NF-E2-related factor 2 (Nrf2;
reviewed in (Johnson et al. 2008)). Nrf2 regulates the ex-
pression of phase-II detoxification and antioxidant enzymes
that share a common DNA binding enhancer sequence, the
antioxidant response element (ARE), recognized by this
transcription factor. Interestingly, Nrf2 is implicated in the
modulation of the innate immune system, including micro-
glial activation following exposure to the well-known SNpc
dopamine neuron toxicant 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP; (Rojo et al. 2010)). In this study,
MPTP-treated Nrf2 knockout mice demonstrated more
nigrostriatal pathology than wild-type mice including en-
hanced gliosis (e.g., increased expression of GFAP and F4/
80) and increased expression of proinflammatory molecules
(e.g., TNF-α) and iNOS, an indicator of oxidative stress
(Rojo et al. 2010). In addition, the overexpression of Nrf2 in
astrocytes was shown to be neuroprotective against oxida-
tive insults (e.g., hydrogen peroxide, MPTP; (Johnson et al.
2008; Chen et al. 2009)). Relevant to misfolded protein
diseases, α-synuclein overexpression in Drosophila leads
to dopamine neuron death that is rescued by the upregula-
tion of phase II detoxification enzymes involved in gluta-
thione metabolism, supporting the hypothesis that Nrf2-
regulated genes are important in the cellular response to
misfolded α-synuclein (Trinh et al. 2008).
In the remainder of this paper we present data supporting
the perception that α-synuclein induces oxidative stress and
promotes microglial inflammation in a conformation-
dependent manner. Our data also supports the idea that cells
respond to α-synuclein-induced oxidative stress by engaging
the Nrf2-antioxidant response system resulting in increased
expression of phase-II detoxification enzymes. Finally we
discuss the concept that initial microglial activation and en-
hanced expression of antioxidant enzymes are appropriate cell
responses and critical to maintain homeostasis; however, pro-
longedmicroglial activation is harmful and promotes neuronal
vulnerability and disease progression.
Methods
Chemicals and reagents
Dulbecco’s Modified Eagle Medium (DMEM) and Minimum
Essential Medium (MEM) were obtained from Cellgro, (St.
Louis, MO). Fetal bovine serum was purchased from Hyclone
(Logan, UT). All other reagents for cell culture and general
use, if not indicated, were obtained from Invitrogen (Carlsbad,
CA) or Sigma-Aldrich (St. Louis, MO).
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Animal studies
Transgenic mice with anti-oxidant response element driven
human placental alkaline phosphatase expression (ARE, a kind
gift of Dr. Johnson; (Johnson et al. 2002)) as well as, a com-
pound transgenic mouse strain carrying both the ARE and
human α-synuclein overexpression under the tyrosine hydrox-
ylase promoter (SARE), were utilized in the specified experi-
ments. The SARE compound transgenics were produced by
breeding SYNWT+/+ (Richfield et al. 2002; Su et al. 2008) with
hemizygous ARE (Johnson et al. 2002) mice to obtain
SYNWT+/+::ARE+/− compound transgenics designated
SARE. All ARE mice were heterozygous for the ARE-
hPLAP gene. Mice were genotyped as previously de-
scribed (Johnson et al. 2002; Richfield et al. 2002). All
mice used for the experiments described here were male.
Animals were maintained and treated in accordance with the
regulatory standards of the Animal Welfare Act and approved
for use by the Georgetown University Animal Care and Use
Committee.
Gene expression analysis
The gene expression of various targets was analyzed using
quantitative real-time PCR (qRT-PCR). Briefly, substantia
nigra and striata were microdissected from ARE and SARE
mice at 1, 6, and 12 months of age (n06 mice/age/geno-
type). Tissues were pooled from two mice of the same age
and genotype and RNAwas isolated using TRIzol® reagent
(Invitrogen, Carlsbad, CA) per manufacturer’s protocol (n0
3 samples/region/genotype/age). RNA quantity and quality
were assessed via standard spectrophotometric methods and
Agilent 2100 Bioanalyzer (Santa Clara, CA; Lombardi
Comprehensive Cancer Center Genomics & Epigenomics
Shared Resource, Georgetown University Medical Center)
following RQ1 DNase treatment (Qiagen, Valencia, CA).
First strand cDNA from the pooled samples was synthesized
from input RNA using the High-Capacity cDNA Archive
Kit (Applied Biosystems, Carlsbad, CA) per manufacturer’s
protocol. Gene expression was quantified in triplicate per
sample using preconfigured TaqMan® low density arrays on
the ABI Prism 7900HT Sequence Detection System (Ap-
plied Biosystems). The following primer/probe sets were
used: 18S (Hs99999901_s1); ABCC1 (Mm00456156_m1);
CAT (Mm00437992_m1); GCLC (Mm00802655_m1);
GCLM (Mm00514996_m1); GPX1 (Mm00656767_g1);
GPX4 (Mm00515041_m1); GSR (Mm00833903_m1); GSS
(Mm00515065_m1); GSTA2 (Mm00833353_mH); HMOX1
(Mm00516004_m1); HMOX2 (Mm00468921_m1); NOX1
(Mm00549170_m1); NQO1 (Mm00500821_m1); PRDX1
(Mm01621996_s1); and TXNRD2 (Mm00496771_m1). Ex-
pression levels were determined using the ΔΔCt method
with 18S rRNA as an endogenous control and age-
matched ARE mice as the comparator. Statistical signifi-
cance was analyzed using one-way ANOVA on the ΔCt
values with post hoc Student’s t-test (p<0.05).
Immunohistochemistry
At the appropriate age, mice were perfused with 4 %
paraformaldehyde under anesthesia and brains were re-
moved, subjected to graded sucrose and microtome sec-
tioned. Forty micron thick free-floating sections were
processed for α-synuclein and tyrosine hydroxylase
(TH) immunohistochemistry (IHC). All incubations were at
room temperature unless noted otherwise. Briefly, sections
were placed into net wells and tissue washed with Tris-
buffered saline (TBS; 3×10 min), permeabilized for 5 min
in TBS + 0.1 % Triton-X-100 (TBST) and blocked for 1 h in
TBST + 10 % normal goat serum. Sections were then incu-
bated with anti-α-synuclein (Thermo Fisher Scientific, Fre-
mont CA; MS-1572-PABX; Syn211; 1:1000) and anti-TH
(Millipore Corp., Temecula CA; AB152; 1:2,000) antibodies
or no primary antibody overnight at 4 °C. Sections were then
washed in TBST (3×10min), followed by incubation with the
appropriate fluorescent secondary antibodies (Life Technolo-
gies Corp; Molecular Probes Inc, Eugene OR; Alexa Fluor®
594 goat-α-mouse IgG and Alexa Fluor® 488 goat-α-rabbit;
1:1000) for 2 h. Sections were subsequently washed in TBST
as above and nuclei stained with 4’,6-Diamidino-2-Phenyl-
indole, Dihydrochloride (DAPI; 0.1 μg/ml; Life Technologies
Corp). Unbound DAPI was removed by incubation with TBS
(3×10 min) and sections were then mounted onto slides using
Citifluor AF1 aqueous mounting media (Ted Pella Inc, Redd-
ing CA). Images were acquired using a Zeiss AxioPlan 2
microscope and Zeiss AxioCam HRm digital camera with
AxioVision LSM image acquisition software (Carl Zeiss,
Thornwood, NY).
Human placental alkaline phosphatase activity
One-, 6-, and 12-month-old ARE and SARE mice (n04/
genotype) were perfused as described above and brains were
removed and post-fixed in 4 % PFA for 1 h at 4 °C. Fixed
brains were then subjected to graded sucrose, cyrostat sec-
tioned (30 μm) and stored at −80 °C until histochemical
analysis. Human placental alkaline phosphatase activity
(hPLAP) was identified following colorimetric detection.
Briefly, sections were removed from −80 °C, placed in a
drying oven for 30 min at 42 °C, immersed in prewarmed
HEPES balanced salt solution (HBSS; Mediatech Inc.,
Herndon, VA) and incubated at 65 °C for 2 h followed by
a 40 min incubation with buffer containing levamisole
(100 mM Tris–HCl, 50 mM MgCl2, 100 mM NaCl, 0.1 %
Tween 20 and 5 mM levamisole) to inactivate endogenous
phosphatases. Sections were then incubated in 5-Bromo-4-
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Chloro-3'-Indolyphosphate p-Toluidine Salt (BCIP)/Nitro-
Blue Tetrazolium Chloride (NBT) reaction buffer
(100 mM Tris–HCl, 50 mM MgCl2, 100 mM NaCl, 0.1 %
Tween 20, 5 mM levamisole, 50 mg/mL BCIP and 37.5 mg/
mL NBT) for 24 h on a slow rotating shaker in the dark. The
reaction was stopped by incubation in PBS. Sections were
analyzed using National Institutes of Health Image J 1.38X
(NIH, Bethesda, MD) software. First, sections were photo-
graphed using an Axiophot microscope under 2.5X magni-
fication. Anatomical regions of interest (e.g., substantia
nigra) were outlined and subjected to the following condi-
tions: the image was converted to 8-bit, scale set to 245.75
pixels/mm global, measurements set to area and limit to
threshold, subtract background selected with a rolling ball
radius of 50 pixels, light background and disable smoothing
selected and a threshold value set at 120. An internal macro
via the Image J program was used to aid in consistency.
Measurements were calculated so that total values represent-
ing the area of deep purple (BCIP/NBT) stain for each
individual animal could be tallied. The values for all brain
sections for each individual animal were summed and sub-
sequently analyzed by ANOVA using Graph Pad Prism 5
software (Graphpad Software Inc., La Jolla, CA).
Expression, purification and characterization of α-synuclein
α-Synuclein was bacterially expressed in Escherichia coli
BL21 (DE3) and purified as previously described, followed
by lyophilization and storage at −20 °C until use (Maguire-
Zeiss et al. 2006). The bacterial α-synuclein expression
vector was a kind gift from Dr. Giasson (Giasson et al.
1999). To obtain misfolded α-synuclein the lyophilized
protein was resuspended by sonication at 20 Hz (2×10 s
bursts with 10 s rest between bursts) and diluted to 1 mg/ml
in buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA, 20 mM
NaCl) followed by incubation for 5 days at 33 °C-37 °C
(SYN) with or without 3.5 mM dopamine prepared in water
(SYNDA). Buffer was incubated in the same manner and
used as the buffer control for all treatments (Buffer or
BufferDA). For some experiments α-synuclein was incubat-
ed for 5 days at 37 °C with constant rotation (1,000 rpm)
followed by size separation into high molecular weight SYN
species (>150 kDa) and low molecular weight SYN as
follows: 300 μg of misfolded SYN was placed onto a
150 kDa molecular weight cut off concentrator (MWCO;
Thermo Fisher Scientific) and centrifuged at 3,000×g for
30 min. The concentrate (HMW SYN) was resuspended in
100 μL of buffer. The flow through was collected and
placed onto a 20 kDa molecular weight cut off concentrator
and centrifuged at 3,000 g for 30 min. This low molecular
weight concentrate (LMW SYN) was resuspended in
100 μL of buffer. The concentration of all protein samples
was assessed using a Bio-Rad DC protein assay. The
endotoxin content of SYN and buffer samples was evaluated
using an E-TOXATE test kit following the manufacturer’s
instructions (Sigma-Aldrich). The detection limit of the kit
was 0.13 Endotoxin Units (EU)/ml (10 EU01 ng).
Western blot analysis
One microgram of SYN was added to denaturing sample
buffer (62.5 mM Tris, pH 6.8, 10 % (v/v) glycerol, 2 % (w/
v) SDS, 5 % (v/v) β-mercaptoethanol, and 1 % (w/v) bromo-
phenol blue), boiled for 90 s and subjected to polyacrylamide
gradient (4–16 %) gel electrophoresis under denaturing con-
ditions followed by transfer to polyvinylidene difluoride
(PVDF) membranes (PerkinElmer, Waltham, MA). A subset
of SYN samples indicated in the figure legends were subjected
to non-denaturing polyacrylamide gel electrophoresis, trans-
ferred to nitrocellulose membranes and processed for western
blot analysis. All membranes were blocked in TBST/NFDM
(20 mM Tris–HCl pH 7.5, 150 mMNaCl, 0.1 % (v/v) Tween,
5 % (w/v) non-fat dry milk). Mouse anti-α-synuclein primary
antibody (1:1000; BDBiosciences, San Jose, CA) was used to
probe for SYN conformers. Immune complexes were visual-
ized on film following incubation with HRP-conjugated goat
anti-mouse 2° antibody (1:2000; Chemicon, Temecula, CA)
using Super Signal West Pico Chemiluminescent Substrate
(Thermo Scientific, Waltham, MA).
Atomic force microscopy
Freshly cleaved muscovite mica was incubated in a mixture
of 1-(3-aminopropyl) silatrane (APS) solution for 30 min to
prepare APS-mica. Manipulated α-synuclein or buffer sam-
ples were added to the APS-mica and allowed to adhere for
2 min, washed with de-ionized water and dried with nitro-
gen gas (Shlyakhtenko et al. 2000, 2003). The mica was
attached to a metal disc with double-sided tape for imaging.
Images were acquired in tapping mode, using silicon tap-
ping mode probes and a Multimode SPM Nanoscope IIIa
system (Veeco/Digital Instruments, Santa Barbara, CA).
Nominal spring constants of 60 N/m and a resonant frequen-
cy of 245 Hz were used.
Cell culture
BV2 and primary microglia treatment
BV2 cells, a murine microglial cell line, were plated at a
density of 5×105 cells per well (6-well plates) in DMEM
supplemented with 5 % fetal bovine serum and allowed to
adhere for 24 h (Blasi et al. 1990; Horvath et al. 2008; Henn
et al. 2009). One hour prior to treatment, serum-containing
media were replaced with serum-free DMEM. Cells were
subsequently treated with an equal volume of SYN (50 nM
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f.c.), SYNDA (50 nM f.c.), Buffer or BufferDA in DMEM for
24 h. Following treatment, media were collected, centri-
fuged at 1,000 rpm for 2 min, placed in fresh tubes and
stored at −20 °C until assayed. All treatments were pre-
formed in triplicate on three separate biological replicates.
Primary microglia cultures were prepared from P1-P3
mouse cortices as previously described (Su et al. 2008),
except that microglia were further isolated from mixed glial
cultures (~DIV 14) by shaking at 125 rpm for 5 h at 37 °C
on a rotary shaker with collection of the microglia-
enriched medium (Beraud et al. 2011). Microglia were
derived from C57/Bl6 or ARE mice (Johnson et al.
2002), plated at a density of 4×104 cells per well (24-
well plates on glass coverslips) in 0.5 mL of MEM
supplemented with 0.01 % pyruvate, 0.6 % glucose
and 5 % fetal bovine serum (microglia growth media)
and allowed to adhere for 24 h. Cells were subsequently
treated with 50 nM SYN or buffer control in microglia
growth media for 24 h as described above. All treatments
were preformed in triplicate on three separate biological rep-
licates. Animals were maintained and treated in accordance
with the regulatory standards of the Animal Welfare Act and
approved for use by the Georgetown University Animal Care
and Use Committee.
TNF-α secretion
TNF-α levels in the media of treated cells were measured by
an enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s instructions (R&D Systems, Minne-
apolis, MN). All measurements were performed in triplicate
on three separate biological replicates.
Nitric oxide release
Nitric oxide (NO) release into the media of treated cells
was determined by measuring the stable NO metabolite,
nitrite, using a Greiss reagent assay kit according to the
manufacturer’s instructions (Invitrogen). All measurements
were performed in triplicate on three separate biological
replicates.
Human placental alkaline phosphatase activity in primary
microglia
Primary microglia from ARE transgenic mice were cul-
tured as described above and treated with 50 nM of
SYN or buffer control for 24 h. Following treatment,
cells were fixed with 4 % paraformaldehyde (w/v)/4 %
sucrose (w/v) solution and stained for alkaline phospha-
tase activity using a BCIP/NBT kit according to the
manufacturer’s instructions (Vector labs, Burlingame,
CA). Resting, activated and phagocytic microglia
displaying phosphatase activity (purple) as well as those
displaying a nuclear counterstain (pink) were enumerat-
ed. Cells from nine random 20x ICC sections per sam-
ple from three coverslips were counted using a Zeiss
AxioPlan 2 microscope (Ontario, NY). Four distinct
groups of cells were counted based on staining and
morphology (circularity, elongation and thickness of pro-
cesses). Cells were considered inactivated/resting if they
had thin and elongated morphology. Activated cells with
thickened processes were categorized based on retraction
and widening of processes. Cells were considered acti-
vated and phagocytic if they had a circular, ameboid
shape. Cells lacking phosphatase activity were classified
as unstained.
RNA extraction and qRT-PCR
Following treatment, RNA was harvested from cultured
cells using an RNeasy mini kit and on-column DNase I
digestion according to the manufacturer’s instructions (Qia-
gen, Valencia, CA). RNA purity was assessed using an
Agilent 2100 Bioanalyzer and concentration measured using
a NanoDrop 1000 spectrophotometer (Thermo Fisher Sci-
entific). RNA was reverse transcribed in a 20 μl reaction
volume using a High-Capacity cDNA Archive Kit (Applied
Biosystems, Carlsbad, CA). The quality of the cDNA was
verified following RT-PCR for β-actin expression. cDNA
samples (10 μl) were then added to 90 μl of TaqMan®
Universal PCR master mix and loaded onto TaqMan®
Low Density Arrays (TLDA) preloaded with probes and
primers for various targets and one endogenous control
(Applied Biosystem; ABI Prism 7900HT Sequence Detec-
tion System; see Figure Legends and Tables). The results
were analyzed using the relative quantification ΔΔCt meth-
od, normalizing samples to 18S rRNA, followed by normal-
ization to the appropriate buffer treated controls. All
measurements were performed in triplicate on three separate
biological replicates. (Primers/Probes used: TNFα
Mm00443258_m1, IL1β Mm0434228_m1, NFĸB1
Mm0047361_m1, TLR1 Mm0120884_m1, TLR2
Mm00442346_m1, TLR3 Mm00446577_g1, TLR4
Mm00445273_m1, TLR6 Mm01208943_s1, TLR7
Mm00446590_m1, TLR9 Mm00446193, MYD88
Mm01351743 and 18S rRNA Hs99999901_s1. For antioxi-
dant response gene primers/probes see 2.2.1. Gene Expres-
sion Analysis. Statistical analysis was performed using a 1-
way ANOVA followed by a Bonferroni post-hoc analysis on
ΔCt values with the significance level set at P≤0.05.
Western blot analysis
BV2 and primary microglia cells were plated and treated
as described above. Following treatment, cells were
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washed with ice-cold PBS and lysed on ice in modified
RIPA buffer (50 mM Tris HCl pH 7.4, 1 % (v/v) NP-40,
0.25 % (w/v) sodium deoxycholate, 150 mM NaCl)
supplemented with Protease Inhibitor Cocktail (for mam-
malian cells; Sigma-Aldrich). Cell lysates were subjected
to gentle rotation for 20 min at 4 °C and then sonicated
at 18 Hz (3×10 s bursts with 30 s rest between bursts).
Lysates were cleared by centrifugation at 17,000 rpm for
10 min at 4 °C. Cleared lysates (25 μg) were treated as
described above and subjected to denaturing polyacryl-
amide gel electrophoresis followed by transfer to PVDF
membranes (PerkinElmer). Membranes were blocked in
TBST/NFDM (20 mM Tris–HCl pH 7.5, 150 mM NaCl,
0.1 % (v/v) Tween, 5 % (w/v) non-fat dry milk) fol-
lowed by incubation with mouse anti-heme oxygenase-1
primary antibody (HO-1; 1:1000; Abcam, Cambridge,
MA). Immune complexes were visualized on film follow-
ing incubation with HRP-conjugated goat anti-mouse 2°
antibody (1:2000; Chemicon) using Super Signal West
Pico Chemiluminescent Substrate (Thermo Scientific).
Membranes were reprobed with α-tubulin (1:1000;
Abcam), which served as the loading control. Densito-
metric analysis of digitized images was performed using
the EC3 Imaging System (UVP, Upland, CA).
Iba-1 Immunocytochemistry
Microglia were plated on glass as described above and
subsequently processed for immunocytochemistry (ICC).
Following treatment, cells were washed with 1X PBS for
5 min, fixed in 4 % PFA at room temperature for 20 min,
permeablized in 1X PBS containing 0.1 % triton X-100
for 5 min and blocked for 1 h with 1X PBS containing
10 % goat serum. Cells were incubated overnight at 4 °C
with rabbit anti-Iba1 antibody (1:750; Wako, Richmond,
VA) in blocking buffer. Antibody:antigen complexes were
visualized following incubation with Alexa Fluor 594
conjugated goat anti-rabbit IgG secondary antibody
1:500. Unbound 2° antibody was removed by washing
with 1X PBS containing 0.1 % triton X-100. Cells were
counterstained with DAPI (1:5000) in 1X PBS for 5 min
and following two washes with 1X PBS the cover glasses
were mounted in Citifluor (Ted Pella, Redding, CA),
sealed and imaged.
Statistical analyses
All statistical analyses were carried out using Graphpad Prism
5 (Graphpad Software Inc., La Jolla, CA) or JMP 9.0.0 (SAS
Institute, Inc., Cary, NC). ANOVAwere performed, followed
by Bonferroni’s post hoc test or Student’s t-test where appro-
priate. All data are reported as means ± standard deviation. P-
values≤0.05 were considered significant.
Results
Increased expression of antioxidant enzymes in mice
that overexpress human α-synuclein
Using two existing transgenic mouse lines, we produced a
new mouse, SARE, which overexpresses human α-
synuclein under the direction of the TH promoter and is
capable of reporting an antioxidant response via expression
of human placental alkaline phosphatase (hPLAP). The
promoter used to drive hPLAP expression in the ARE and
SARE mice contains 51-base pairs of the rat NAD(P)H:
quinone oxidoreductase 1 (NQO1) promoter including the
core antioxidant response element (5’-GTGACnnnGC-3’)
(Johnson et al. 2002). It was previously established by
Johnson et al., that cultured neurons and glia from ARE
mice express hPLAP when treated with tBHQ (tert-butylhy-
droquinone), a molecule known to activate ARE through an
Nrf2-mediated mechanism (Johnson et al. 2002; Kraft et al.
2004). Therefore we reasoned that these reporter mice
crossed with α-synuclein overexpressing mice would reveal
spatial and temporal synuclein-initiated antioxidant
responses. Towards this goal, groups of SARE and ARE
mice at 1-, 6- and 12-months of age were prepared for IHC
and hPLAP activity. As shown in Fig. 1, SARE mice exhibit
co-localization of TH and α-synuclein at all ages in SNpc
neurons and attendant presynaptic terminals in the striatum.
There were no apparent pathological effects of α-synuclein
overexpression at these ages following microscopic inspec-
tion. We next examined the ARE antioxidant response by
colorimetric identification of hPLAP activity (Fig. 2a). Here
we demonstrate that the SNpc exhibits an increased antiox-
idant response compared with surrounding brain regions.
Using this method we did not detect a statistically signifi-
cant difference in phosphatase activity between the ARE
and SARE mice (Fig. 2b).
We next employed a more sensitive assay, qRT-PCR, to
determine whether a subset of known Nrf2-regulated genes
displayed altered expression when α-synuclein was overex-
pressed. RNAwas prepared from the SN and striata of 1-, 6-
and 12-month old SARE and ARE mice, reverse transcribed
and gene expression levels quantified using preconfigured
TaqMan® low density arrays. Using 1-month ARE mice as
the comparator, α-synuclein overexpression increased the
nigral and striatal gene expression level for a number of the
antioxidant enzymes interrogated at 1-month of age
(Table 1). In the SN of SARE mice, genes that regulate
glutathione metabolism: glutamate-cysteine ligase (GCLC),
glutamate-cysteine ligase regulatory subunit (GCLM) and
glutathione synthetase (GSS) were increased nearly 2-fold
compared to ARE mice. Genes associated with the detoxi-
fication of hydrogen peroxide and quinones were also upre-
gulated in 1-month old SARE mice (glutathione peroxidase-
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1/GPX1, glutathione peroxidase-4/GPX4, heme oxygenase-
1/HMOX1, NAD(P)H dehydrogenase, quinone 1/NQO1;
catalase/CAT). ABCC1, which encodes for a superfamily
of ATP-binding cassette transporters, including the multi-
drug resistance-associated protein-1, and functions with ox-
idized glutathione to transport molecules across membranes
was increased 2-fold in 1-month old SARE mice. Likewise
gene expression levels in the striatum were upregulated in 1-
month old SARE mice. In the SN the expression levels for
these genes returned to ARE levels at subsequent time-
points. Interestingly, expression levels at 1- and 6-months
of age for SARE striatal genes associated with the detoxifi-
cation of hydrogen peroxide and quinones as well as
glutathione metabolism remained upregulated compared
with age-matched ARE mice (Fig. 3).
Microglia respond differently to specific types
of α-synuclein
We have previously demonstrated that α-synuclein contain-
ing β-sheet structures increases microglial activation that is
consistent with a classical activation pathway (Beraud et al.
2011). Here we extend those studies and ask whether dif-
ferent forms of misfolded α-synuclein similarly activate
microglia. As discussed above, α-synuclein will readily
misfold into oligomers and high molecular weight
Fig. 1 α-Synuclein and TH co-
localize in the SNpc and stria-
tum of SARE mice. Substantia
nigra a and striatal b images
from 1-month old SARE and
ARE mice following co-
immunohistochemistry for
tyrosine hydroxylase
(TH; green) and α-synuclein
(SYN; red) demonstrating
co-localization (Merge; yellow)
of these proteins in mice that
overexpress human α-synuclein
under the control of a rat TH
promoter (SARE). Images were
taken at 10X (scale bar 0
100 μm) and 100X (scale bar 0
10 μm) magnifications
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aggregates in response to molecular crowding, agitation,
temperature, and following incubation with dopamine
(DA). Therefore we expressed and purified recombinant
human wild-type α-synuclein and induced aggregation us-
ing temperature, rotation and/or DA (SYN; SYNDA). Buffer
controls (i.e., no α-synuclein) were similarly treated (Buffer,
BufferDA). The resultant α-synuclein conformers and buffer
controls were subsequently tested for endotoxin contamina-
tion, which was found to be below the detectable limit of the
assay (< 0.013 ng/ml). To determine whether SDS-stable
oligomers were present in these samples, SYN and SYNDA
were subjected to polyacrylamide gel electrophoresis under
denaturing conditions followed by western blot analysis for
α-synuclein. As shown in Fig. 4a, both SYN and SYNDA
contain monomeric as well as SDS-stable oligomers of α-
synuclein. However, SYNDAwas comprised of significantly
more high molecular weight α-synuclein aggregates than
SYN. We also characterized SYN and SYNDA under non-
denaturing conditions using atomic force microscopy
(AFM) to visualize and quantify the height distribution of
the manipulated proteins (Fig. 4b & c). The predominant
molecular height of SYN was less than 5 nm (70 %), repre-
senting monomeric α-synuclein, while approximately 10 %
of the α-synuclein molecules were aggregates of greater
than 10 nm. Conversely, dopamine-modified α-synuclein
contained a significantly greater number of aggregates with
a molecular height >10 nm (59 %) and nearly 1.9-fold more
detectable molecules at this height than SYN. Together,
these data show that both SYN and SYNDA contain mono-
mer and aggregates of α-synuclein and that dopamine-
Fig. 2 Antioxidant responses in vivo. The SNpc of 1-, 6- and 12-
month old ARE and SARE mice (n04/genotype/age) were processed
for hPLAP activity measurements using a BCIP/NBT staining proto-
col. a Image of phosphatase activity in the SNpc of an SARE mouse
(12-months of age) demonstrating robust activity in this region of the
brain (white arrows). Images were taken at 10X (scale bar 0 100 μm)
magnification. b The density of phosphatase activity was determined
from the SNpc of BCIP/NBT stained tissue for all mice and reported as
pixels/mm2. There is no statistically significant difference between α-
synuclein overexpressing mice (SARE) and ARE mice in phosphatase
activity
Table 1 Oxidative stress gene
expression changes in 1-month old
α-synuclein overexpressing mice
Expression data in each brain re-
gion represents changes in 1-month
oldmice that overexpress humanα-
synuclein and carry the ARE-
hPLAP transgene (SARE) com-
pared to AREhPLAP mice (ARE),
which do not overexpress human
α-synuclein. The expression levels
of GSTA2 and HMOX2 were be-
low the limit of detection and are
not included in this table. 1ND
indicates expression levels below
the limit of detection;↔ indicates
no significant difference in gene
expression between SARE and
ARE mice. P≤0.05
Entrez Gene ID Common Name Description Fold change in gene
expression by brain region1
Substantia Nigra Striatum
17250 ABCC1 ATP binding cassette C ↑ 2.0 ↔
12359 CAT Catalase ↑ 2.0 ↑1.4
14629 GCLC Glutamate-cysteine ligase-catalytic ↑ 1.8 ↔
14630 GCLM Glutamate-cysteine ligase-modifier ↑ 2.0 ↑ 2.5
14775 GPX1 Glutathione peroxidase 1 ↑ 1.5 ↑ 2.4
14854 GSS Glutathione synthetase ↑ 1.8 ↑ 2.5
14782 GSR Glutathione reductase ↑ 1.8 ↑ 2.5
625249 GPX4 Glutathione peroxidase 4 ↑ 1.5 ↑ 2.2
15368 HMOX1 Heme oxygenase 1 ↑ 1.6 ↑ 2.1
237038 NOX1 NADPH oxidase I ND ↔
18104 NQO1 NADPH dehydrogenase quinone 1 ↑ 1.6 ↑ 2.5
18477 PRDX1 Peroxiredoxin 1 ↔ ↑ 2.3
26462 TXNRD2 Thioredoxin reductase 2 ↔ ↑ 2.4
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modification enhances the propensity for α-synuclein to
form larger aggregates.
To determine whether these differentially modified
forms of α-synuclein induce a proinflammatory response
in microglia we exposed BV2 cells, an immortalized mouse
microglial cell line, to SYN and SYNDA as well as buffer
controls and assayed for prototypical proinflammatory mol-
ecules. Conditioned media from treated BV2s were assayed
Fig. 3 α-Synuclein overexpression increases the expression of anti-
oxidant genes in the striatum. Quantitative RT-PCR was performed on
cDNA obtained from 1-, 6- and 12-month old ARE and SARE mouse
striata. a SARE mice had significantly higher expression of genes
associated with the detoxification of hydrogen peroxide and quinones
(HMOX1, NQO1, GPX1 and GPX4) at 1- and 6-months of age com-
pared with age-matched ARE mice. b SARE mice had significantly
higher expression of genes associated with glutathione metabolism
(GCLM, GSS and GSR) at 1- and 6-months of age compared with
age-matched ARE mice. Expression values were normalized to 18S
rRNA as an internal control. All SARE measurements at 1- and 6-
months of age were significantly different than ARE at the same ages
(P<0.05). The dashed line represents the gene expression level of ARE
mice. Data expressed as fold change (2-ΔΔct) ± S.D
Fig. 4 Characterization of misfolded α-synuclein. α-Synuclein was
incubated at 33–37 °C in the absence (SYN) or presence of dopamine
(SYNDA) and characterized by western blot analysis following poly-
acrylamide gel electrophoresis under denaturing conditions (SDS-
PAGE) or by AFM under native conditions. Dopamine modification
of α-synuclein caused an increase in high molecular weight aggre-
gates. a Western blot analysis of manipulated α-synuclein demonstrat-
ed an increase in SDS-stable, high molecular weight oligomers
following dopamine modification (SYNDA). α-Synuclein samples
were subjected to 4–16 % SDS-PAGE and immunoblotted for α-
synuclein. Both short and long film exposures are shown; *denotes
the stacking/resolving gel interface. Short exposure corresponds to a
2 s exposure time for the film, while the long exposure is a 15 s
exposure time. b AFM demonstrated an increase in α-synuclein aggre-
gates following incubation with heat and dopamine. c Quantification of
AFM molecular height images demonstrated that incubation of α-
synuclein in the presence of dopamine (SYNDA; black) resulted in a
10-fold increase in aggregates >10 nm with a concomitant decrease in
molecules <5 nm in height compared to α-synuclein without dopamine
(SYN; grey). Molecular height images are shown at 3 μm×3 μm×
3 μm
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for the amount of nitrite, a stable NO metabolite. NO
secretion from cells treated with SYN was significantly
increased compared with buffer- or dopamine-modified α-
synuclein (SYNDA; Fig. 5a; P≤0.05). In fact, NO was
undetectable following SYNDA, Buffer or BufferDA treat-
ment of BV2 cells. We next quantified the amount of a
common proinflammatory cytokine, TNF-α, released by
the treated BV2s. Similar to the NO production, exposure
to SYN induced the release of ~900 pg/ml of TNF-α,
which is typical of classically activated microglia while
SYNDA- or buffer-treatment had little effect on TNF-α
release (Fig. 5b; P≤0.05; (Beraud et al. 2011)). Likewise,
TNFα gene expression was upregulated 14-fold in BV2s
treated with SYN, while SYNDA-treated BV2s exhibited no
significant difference in expression compared to buffer-
treated cells (Table 2).
Since we have previously shown that IL1β mRNA ex-
pression is robustly increased in BV2 cells following α-
synuclein treatment (Beraud et al. 2011), we next deter-
mined whether α-synuclein treatment altered the expression
of this cytokine. When compared to their respective buffer
controls, IL1β gene expression was significantly increased
following exposure of BV2 cells to either SYN or SYNDA.
However, the fold-increase in IL1β gene expression was 56-
fold for the SYN-treated BV2 cells and only 2.7-fold for
BV2s treated with SYNDA (Table 2). Taken together, these
data establish that a mixture of α-synuclein containing both
monomeric and high molecular weight conformers of this
protein significantly augments the expression, production
and release of classical proinflammatory molecules from
BV2 cells, while α-synuclein misfolded in the presence of
dopamine (SYNDA) causes a dampened response, despite
Fig. 5 SYN induces a classical activation pattern in BV2 cells. SYN
causes conformer-specific increases in proinflammatory molecule ex-
pression and release. a BV2 cells were treated with 50 nM SYN,
50 nM SYNDA or equal volumes of the appropriate buffer control for
24 h. Following treatment, a Greiss reagent assay was performed on the
conditioned media to determine nitrite production. Conditioned media
from SYN-treated BV2 cells had a substantial amount of nitrite
(70 μM); in contrast there was no detectable (N.D.) NO in the media
of cells treated with SYNDA or in media from buffer treated cells; (*p<
0.05). b BV2 cells were treated as described above and TNF-α protein
was quantified in the conditioned media by ELISA. TNF-α release
from BV2 cells was significantly increased in SYN-treated BV2 cells
compared to the DA-modified SYN-treated (SYNDA) cells; there was
no detectable (N.D.) TNF-α in media from buffer treated cells; (*p<
0.05). All values represent three biological replicates with treatments in
triplicate
Table 2 Inflammatory gene ex-
pression changes following SYN
treatment of BV-2 microglia
BV-2 microglia were treated
with 50 nM of SYN, SYNDA or
appropriate buffer for 24 h. 1
↔indicates no significant differ-
ence in gene expression com-
pared to buffer treated cells P≤
0.05; ND indicates expression
levels below the limit of detec-
tion. *denotes a significant dif-
ference in gene expression fold
change between SYN and
SYNDA treated cells at P≤0.05




21897 TLR1 Toll-like receptor 1 ↔ ↔
24088 TLR2 Toll-like receptor 2 ↑ 2.0 ↔
142980 TLR3 Toll-like receptor 3* ↑ 3.7 ↔
21898 TLR4 Toll-like receptor 4 ↓ 0.7 ↔
21899 TLR6 Toll-like receptor 6 ↔ ↔
170743 TLR7 Toll-like receptor 7* ↓ 3.0 ↔
81897 TLR9 Toll-like receptor 9 ↔ ↔
20778 CD36 Scavenger receptor class b member 1 ↔ ↔
16176 IL1β Interleukin 1 beta* ↑ 56 ↑ 2.7
21926 TNFα Tumor necrosis factor alpha* ↑ 14 ↔
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the presence of high molecular weight α-synuclein species
suggesting that the structure of α-synuclein modified by
dopamine is different than α-synuclein modified in the
absence of this neurotransmitter.
Microglial activation can be mediated by engagement of
DAMPs to cognate pattern recognition receptors and these
interactions are structure dependent. Therefore, we next asked
whether the expression of a subset of these receptors was
altered inBV2 cells followingα-synuclein treatment (Table 2).
Specifically, we interrogated genes encoding toll-like receptor
(TLR) 1, 2, 3, 4, 6, 7 and 9, scavenger receptor CD36 as well
as proteins involved in TLR and microglial activation (NFĸB;
MyD88). SYN-treated BV2 cells demonstrated increased ex-
pression of TLR2 and TLR3 with a down regulation of TLR4
and TLR7 compared to buffer-treated BV2s. There were no
significant changes in the expression levels for TLR1, 6, 9,
CD36, NFĸB or MYD88. In contrast, BV2s exposed to
dopamine-modified α-synuclein (SYNDA) did not exhibit a
significant gene expression change for TLRs, CD36, NFkB or
MYD88 (Table 2), which supports our previous data demon-
strating that SYNDA did not induce a proinflammatory
response.
Since SYN which contains both monomeric and oligo-
meric protein caused an increase in TNF-α, IL-1β and
several TLRs and dopamine-modified α-synuclein had ei-
ther no or a less robust effect on these molecules we rea-
soned that protein structure is important for glial activation.
To address this hypothesis, we misfolded α-synuclein and
enriched for high (> 150 kDa; HMW) and low molecular
weight (~ 20 kDa; LMW) structures using molecular weight
cut off concentrators. Fig. 6a shows the relative purity of
these fractions following western blot analysis of non-
denatured α-synuclein before (SYN) and after separation
(HMW SYN; LMW SYN). We then exposed primary
microglial cultures derived from mouse cortices to HMW
SYN, LMW SYN or buffer and quantified TNF-α release
(Fig. 6b). Only the HMW SYN fraction robustly increased
the release of this prototypical proinflammatory cytokine. In
addition, morphological analysis of Iba1+ cells revealed a
predominant increase in ameboid microglia following treat-
ment with HMW SYN, a structure consistent with highly
activated phagocytic microglia (Fig. 6c). These results are
consistent with the hypothesis that α-synuclein structure
directs the extent and the nature of the microglial response.
α-Synuclein induces an antioxidant response in microglia
As discussed above one consequence of NO and proinflam-
matory molecule production is an overall increase in oxida-
tive stress and microglia respond by increasing the
expression of antioxidant response genes in an attempt to
maintain homeostasis (Chowdhury et al. 2009; Bast et al.
2010). Since the upregulation of these phase-II
detoxification enzymes regulated in part by the transcription
factor, Nrf2, provides cellular protection from oxidative
stress, we next asked whether exposure of microglia to
various forms of α-synuclein enabled an antioxidant re-
sponse. Primary microglia derived from ARE reporter mice
(Johnson et al. 2002, 2008) were exposed to SYN, SYNDA
or buffer controls and analyzed for hPLAP activity (Fig. 7).
All treated cells had a subset of glia with phosphatase
activity; however, the majority of microglia (>75 %) ex-
posed to buffer only maintained a ramified morphology with
small cell bodies and long processes typical of non-activated
microglia (Panels a, b, e & f; dashed arrows and quantified
in Panel i). However, these microglia also had a subset of
cells with larger cell bodies and shorter processes, consistent
with an activated but not phagocytic morphology (Panel f;
solid arrow and quantified in Panel i). In contrast, ARE
microglia exposed to SYN or SYNDA displayed a robust
change in morphology to an ameboid shape, consistent with
microglia that are highly activated and/or phagocytic (Pan-
els c, d, g & h; solid arrowheads and quantified in Panel i).
The primary microglia exposed to dopamine-modified α-
synuclein (SYNDA) had increased numbers of microglia
with thickened processes (activated but not phagocytic)
compared to the SYN-treated microglia.
We next investigated whether the antioxidant genes that
were upregulated in the α-synuclein overexpressing mice
(Table 1) were altered in microglia exposed to misfolded α-
synuclein. The overall response following SYN or SYNDA
exposure of BV2s was an upregulation of antioxidant re-
sponse gene expression (Table 3), which is in alignment
with the phosphatase activity measurements in primary
microglia (Fig. 6). There was also a robust increase in
NADPH oxidase 1 (NOX1) gene expression in SYN-
treated microglia (240-fold increase). This enzyme gener-
ates superoxide ion promoting the formation of NO and IL-
1β in LPS-treated microglia (Cheret et al. 2008) and its
upregulation here is in line with our data demonstrating that
SYN-treated microglia have an activation profile that
includes increased levels of NO, TNF-α and IL-1β. For
nearly all of the interrogated genes the response to SYN
was significantly different from SYNDA-treated BV2 cells,
translating into a less robust antioxidant response following
SYNDA treatment as well as a weakened proinflammatory
response. Importantly, there were no significant differences
in gene expression levels when Buffer-treated BV2 cells
were compared to BufferDA-treated cells suggesting that
the gene expression changes following SYNDA treatment
was due to SYNDA not free DA.
Since, the antioxidant enzyme, HO-1 is upregulated fol-
lowing exposure to α-synuclein and in our α-synuclein
overexpressing mice (Table 1; Fig. 3 and (Kitamura et al.
1998a, b; Tanaka et al. 2006; Bast et al. 2010; Beraud et al.
2011; Lastres-Becker et al. 2012)), we next examined HO-1
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protein levels from microglia treated with different forms of
α-synuclein. Both SYN and SYNDA caused a significant
upregulation of HO-1 protein (Fig. 8a & b; P≤0.05).
BufferDA treatment also increased HO-1 expression support-
ing previous evidence that DA alone promotes oxidative
stress and increases HO-1 expression (Schmidt et al.
1999). HMW SYN, which caused an increase in TNF-α
and a robust morphological change in primary microglia
also increased HO-1 expression in these cells while LMW
SYN did not affect the expression of this antioxidant
(Fig. 9). Taken together, these data demonstrate a robust
antioxidant response following treatment of microglia with
high molecular weight aggregates of α-synuclein as dem-
onstrated by an increase in ARE-directed hPLAP activity,
morphological changes typical of phagocytic and activated
microglia and enhanced expression of proinflammatory
molecules and antioxidant response enzymes. In contrast,
dopamine modified α-synuclein did not induce a robust
TNF-α response nor increase NO but did increase the
expression of HO-1. HO-1 protein was also upregulated in
microglia exposed to DA alone in the absence of any
proinflammation.
Discussion
In 1988, the potential role for inflammation in Parkinson’s
disease (PD) pathogenesis was suggested when McGeer’s
group demonstrated an increase in reactive microglia (HLA-
DR-positive) in the substantia nigra of PD brains (McGeer
et al. 1988). Since that time, a GWA study identified an
HLA locus (rs3129882 of HLA-DR) as a risk factor for
sporadic PD (Hamza et al. 2010). Furthermore, in vivo
imaging supports that glial activation is present in the early
stages of PD and this activation increases as the disease
progresses (Ouchi et al. 2005; Gerhard et al. 2006; Ouchi
et al. 2009). Genetic and neurotoxicant animal models tar-
geting the nigrostriatal pathway also substantiate a role for
Fig. 6 HMW α-synuclein activates microglia. a Representative α-
synuclein western blots of misfolded α-synuclein under native con-
ditions. Purified human recombinant α-synuclein was incubated at 37 °
C with 1000 rpm rotation for 5 days to induce misfolding (SYN).
Misfolded SYN was then separated into high molecular weight
(HMW SYN) and low molecular weight (LMW SYN) fractions using
MWCO concentrators. b Primary microglia were treated with buffer,
LMW SYN (50 nM) or HMW SYN (50 nM) for 24 h. Following
treatment, the conditioned media was evaluated for TNF-α protein
secretion using an ELISA. Cells treated with HMW SYN released
significantly more TNF-α than Buffer or LMW SYN treated microglia
(*P<0.05, n03). c Primary microglia were treated with buffer, 50 nM
of LMW SYN or 50 nM HMW SYN for 24 h. Cells were fixed and
immunostained for the microglial marker Iba-1 (red) followed by a
DAPI nuclear counterstain (blue). The majority of primary microglia
treated with buffer or LMW SYN display prototypical ramified mor-
phology of resting microglia while glia treated with HMW SYN
display the characteristic ameboid shape of activated microglia (scale
bar 0 20 μm)
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microglial activation and oxidative stress in response to PD-
relevant stressors prior to neuron death (Czlonkowska et al.
1996; Cicchetti et al. 2002; Depino et al. 2003; Kim and Joh
2006; Liu 2006; Qian et al. 2006a; Su et al. 2008, 2009).
However, the exact role activated microglia play in PD is
unclear as microglia are associated with both repair and
toxicity. Furthermore the term “activation” does not ade-
quately describe the complex morphological and functional
change microglia undergo when reacting to changes in the
microenvironment (discussed in (Colton and Wilcock 2010;
Harry and Kraft 2012)).
Conventional dogma classifies activated microglia as
those glia with larger cell bodies and thicker, less-ramified
processes and that release proinflammatory cytokines such
as TNF-α and IL-1β, as well as molecules indicative of
increased oxidative stress (e.g., NO). Additional sub-
classes within the classical activation categorization
have been proposed more recently based on the expres-
sion of cytoactive factors that result in inflammotoxic-,
excitotoxic- and redox-mediated activation states, which
further supports the idea that complex and intricate
molecular interactions result from microglial activation
(Colton and Wilcock 2010). Microglia are also activated
in an alternative pathway that promotes immunological
resolution via the production of neurotrophic factors,
anti-inflammatory cytokines (i.e., IL-10, IL-4), arginase
I, matrix metalloproteinases and antioxidant response pro-
teins (i.e., HO-1; reviewed in (Colton and Wilcock 2010)).
Therefore, microglia can quickly react and respond to danger/
damage signals in a complex manner that facilitates the
Fig. 7 Exposure of primary microglia to α-synuclein increases anti-
oxidant expression. Primary microglia from ARE transgenic mice were
histochemically stained with BCIP/NBT (purple) to detect hPLAP
activity and nuclear red counterstained (pink). Microglia exposed to
Buffer (a, b) or BufferDA (e, f) displayed less phosphatase activity than
SYN-treated cells and also exhibited the prototypic morphology of
resting microglia (dashed arrows; a, b, e, f & i) with a few glia that
were activated but not phagocytic (solid arrows). In contrast, cells
exposed to SYN or SYNDA displayed increased numbers of microglia
with the characteristic amoeboid morphology of phagocytic microglia
compared to the other exposure paradigms (solid arrowheads; c, d, g,
h & i). Interestingly, microglia exposed to SYNDA had the greatest
percentage of microglia expressing phosphatase activity with nearly
75 % of the treated microglia activated, as demonstrated by thickened
processes and ameboid shape (solid arrow and solid arrowhead, re-
spectively; g, h & i). Scale bar for 10x (a, c, e, g) and 40x (b, d, f, h)
images represent 100 µm and 20 µm respectively. Boxes in a, c, e, and
g denote the area for 40x images b, d, f and h. Cell counts were
performed on nine random 20x images from each sample and catego-
rized based on staining and morphology as outlined in Materials and
Methods (i)
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destruction and/or removal of these molecules as well as the
initiation of subsequent repair and/or immunological resolu-
tion. This ability places microglia in a position to significantly
affect brain homeostasis.
In neurodegenerative disorders, including PD, it is hy-
pothesized that persistent oxidative stress and proinflamma-
tory activation of microglia contribute to the death of
surrounding neurons (e.g., toxicity); however, it is also
possible that activation of microglia is an attempt at
immunological resolution and that only with continued neu-
rodegeneration is the balance tipped toward toxicity
(Fig. 10). We suggest the following critical factors deter-
mine the outcome of microglial activation (e.g., toxicity vs.
resolution): the microenvironment (e.g., nigrostriatal sys-
tem), the temporal aspects of the microglial response (e.g.,
early vs. late in disease) and the inciting danger/damage
molecular pattern (e.g., specific conformation of α-
synuclein). In the studies presented here we focused on α-
Table 3 Oxidative stress gene
expression changes following
SYN treatment of BV-2
microglia
BV-2 microglia were treated
with 50 nM of SYN, SYNDA or
appropriate buffer for 24 h. 1↔
indicates no significant differ-
ence in gene expression com-
pared to buffer treated cells P≤
0.05; ND indicates expression
levels below the limit of detec-
tion. *denotes a significant dif-
ference in gene expression fold
change between SYN and
SYNDA treated cells at P≤0.05




14775 GPX1 Glutathione peroxidase 1* ↓ 0.7 ↔
18477 PRDX1 Peroxiredoxin 1* ↑ 3.5 ↑1.4
14858 GSTA2 Glutathione S transferase, alpha 2* ↑ 500 ↑ 60
18104 NQO1 NADPH dehydrogenase quinone 1* ↑ 6.0 ↑ 4.0
15368 HMOX1 Heme oxygenase 1* ↑ 4.0 ↑ 2.0
15369 HMOX2 Heme oxygenase 2 ND ND
12359 CAT Catalase* ↑ 2.4 ↑ 2.0
14630 GCLM Glutamate-cysteine ligase-modifier ↑ 3.0 ↑2.5
14629 GCLC Glutamate-cysteine ligase-catalytic ↔ ↔
14854 GSS Glutathione synthetase* ↓ 0.6 ↓ 0.9
14782 GSR Glutathione reductase* ↑ 2.5 ↑ 1.5
17250 ABCC1 ATP binding cassette C* ↑ 2 ↑ 1.3
237038 NOX NADPH oxidase 1 ↑ 240 ↑ 61
26462 TXNRD2 Thioredoxin reductase 2* ↓ 0.4 ↓ 0.6
625249 GPX4 Glutathione peroxidase 4* ↓0.7 ↔
Fig. 8 Exposure of microglia to α-synuclein or dopamine increases
HO-1 protein expression. a Representative HO-1 western blot analysis
of BV2 lysates. BV2 cells were treated with 50 nM of SYN or SYNDA
or equal volumes of the appropriate buffer control for 24-h. Protein
lysates were prepared and subjected to 10 % SDS-PAGE and immuno-
blotted for HO-1 (~32 kDa). Blots were re-probed for α-tubulin
(~50 kDa) as a loading control. b Immunocomplexes were quantified
by densitometric analysis. The HO-1 signal was normalized to the
loading control. Cells treated with SYN or SYNDA had significantly
higher levels of HO-1 expression compared to buffer alone (*p<0.05,
1-way ANOVA followed by Student’s t post-test). Additionally, the
presence of DA alone was enough to significantly increase HO-1
expression. Cells treated with buffer that was incubated in the presence
of DA (BufferDA) had significantly higher levels of HO-1 than buffer
incubated in the absence of DA (*p<0.05, 1-way ANOVA followed by
Student’s t post-test). Values represent three biological replicates with
treatments in triplicate
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synuclein as the danger/damage molecular pattern and char-
acterized the antioxidant response in an animal model of
overexpression as well as the proinflammatory and antiox-
idant responses in microglia.
Our data support the hypothesis that α-synuclein contrib-
utes to oxidative stress through a pathway that induces
complex microglial activation as well as antioxidant
responses and in addition requires a specific protein struc-
ture (Fig. 10). First, we demonstrate that in an animal model
of α-synuclein overexpression there is an increase in the
nigrostriatal expression of genes involved in cellular
responses to oxidative stress. We interrogated genes that
are known to be regulated by the master regulator of anti-
oxidant responses, Nrf2, in a novel animal model of α-
synuclein overexpression in the context of an antioxidant
reporter transgene (SARE) generated by crossing mice ho-
mozygous for human α-synuclein (SWT+/+; (Su et al.
2008)) with AREhPLAP transgenic mice (Johnson et al.
2002). Relevant to the studies presented here, at one-
month of age α-synuclein transgenic mice (SWT+/+) exhib-
it increased numbers of activated microglia in the SNpc as
well as increased expression of TNFα in the SN and stria-
tum, demonstrating an early microglial activation driven by
the overexpression of α-synuclein (Su et al. 2008). Here we
also show that genes associated with the detoxification of
hydrogen peroxide and quinones as well as those involved
in glutathione metabolism remain increased in the striatum
of α-synuclein overexpressors (SARE mice) compared with
age-matched controls (ARE mice) up to 6-months of age.
More studies are needed to define the importance of these
gene expression changes but it is interesting to speculate that
the upregulation of these genes is in response to the early
microglial activation previously described and that these
early antioxidant responses are capable of restoring homeo-
stasis since this model does not display significant nigros-
triatal pathology or glial activation at older ages (Richfield
et al. 2002). Other models of α-synuclein overexpression
also display glial activation supporting the ability of this
protein to induce inflammation in vivo (Theodore et al.
2008; Chesselet et al. 2012). However, the cellular response
to oxidative stress is complex, partially mediated through
engagement of the Nrf2 transcription factor to its cognate
DNA binding site (Johnson et al. 2008) but other transcrip-
tion factors including activator protein 1 (AP1), cAMP
response element binding protein (CREB), activating tran-
scription factor 2 (ATF2) and nuclear factor kappa B
(NFĸB) activator are also important for the regulation of
these genes (Kim et al. 2011b). Adding to the complexity
some genes (NQO1, glutathione S-transferase P, [GSTP1]
and methallothionein [MT1 & 2]) that contain a typical Nrf2
antioxidant response element (ARE) are also regulated by
another Cap‘n’Collar transcription factor, Nrf1 (Leung et al.
2003; Ohtsuji et al. 2008). Although mechanistic studies
are needed to confirm that Nrf2-mediated responses are
at play when α-synuclein is overexpressed in our mod-
el, Lastres-Becker et al. used adeno-associated viral
vector delivery of human α-synuclein in Nrf2 knockout
(Nrf2-KO) mice and demonstrated increased nigrostriatal
pathology (Lastres-Becker et al. 2012). Furthermore,
Nrf2-KO mice exposed to the nigrostriatal neurotoxi-
cant, MPTP, have enhanced microgliosis with increased
levels of proinflammatory markers and decreased expression
of proteins associated with alternative activation, supporting a
role for Nrf2 in modulating microglial activation states (Rojo
et al. 2010).
Second, here we confirm and extend previous work dem-
onstrating that α-synuclein directly activates microglia in a
classical proinflammatory activation pathway. We previous-
ly demonstrated that misfolded human α-synuclein directly
activates microglia via the classical pathway with increased
expression of a subset of pattern recognition receptors,
known to bind DAMPs (Beraud et al. 2011). In the current
study we asked whether different types of misfolded α-
synuclein induce the same microglial activation pattern
Fig. 9 Exposure of microglia to HMW α-synuclein increases HO-1
protein expression. a Representative HO-1 western blot analysis. Pri-
mary microglia were treated with 5 nM of LMW SYN, HMW SYN or
buffer control for 24-h. Protein lysates were prepared and subjected to
4–20 % SDS-PAGE and immunoblotted for HO-1 (~32 kDa). Blots
were re-probed for α-tubulin (~50 kDa) as a loading control. b
Immunocomplexes were quantified by densitometric analysis. The
HO-1 signal was normalized to the loading control. Cells treated with
HMW SYN had significantly higher levels of HO-1 expression com-
pared to buffer or LMW SYN (*p<0.05, 1-way ANOVA followed by
Student’s t post-test)
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and in addition promote an antioxidant response. Our data
confirms a highly complex microglial response to different
types of α-synuclein. We show that α-synuclein containing
high molecular weight SDS-stable species activates micro-
glia in a classical proinflammatory activation pathway. In
contrast, ‘monomeric’ α-synuclein does not induce a proin-
flammatory response. However, high molecular weight
aggregation as defined by gel electrophoresis or AFM is
not the only criteria for activation since in our hands α-
synuclein modified by dopamine (SYNDA) does not cause a
robust proinflammatory response. This suggests that a spe-
cific secondary structure is required for activation that is
present in SYN but not SYNDA. Our data also support this
idea since the expression of TLR pattern recognition
Fig. 10 Schematic diagram depicting the effect of α-synuclein on
microglia and PD. α-Synuclein promotes microglial activation in a
structure dependent manner contributing to PD pathogenesis. Data
presented in this paper supports the hypothesis that a specific structure
is required to directly activate microglia and that antioxidant responses
are in response to α-synuclein overexpression and direct glial activa-
tion. a Monomeric α-synuclein (red line) does not directly activate
microglia. b Protofibrils stabilized by dopamine (−DA*) and amor-
phous aggregates of α-synuclein increase microglial expression of
antioxidant enzymes and have an attenuated proinflammatory response
(modest increase in IL1β), which we hypothesize leads to immuno-
resolution rather than toxic inflammation. c Fibrils of α-synuclein
directly activate microglia in a classic proinflammatory pathway (high
levels of NO, NOX1, TNF-α and IL1β). Even though antioxidant
enzymes are upregulated they cannot quell this robust glial activation.
We further suggest that fibrillar α-synuclein is recognized by specific
microglial PRRs, which facilitate a proinflammatory pathway. These
highly activated cells would be immune-toxic for surrounding neurons.
d Parkinson’s disease pathogenesis schematic. SNpc dopamine
neurons normally express α-synuclein and this protein is enriched in
striatal presynaptic dopamine terminals. If α-synuclein maintains a
random coil structure this protein does not activate microglia (far left).
When α-synuclein forms a protofibillar structure (e.g., due to over-
expression, oxidative stress, the presence of dopamine quinone) micro-
glia respond by increasing the expression of antioxidant enzymes and
take on an activated morphology that we suggest is an attempt to return
the microenvironment to homeostasis (middle). However, as opposed
to pure microglial cultures, in this in vivo setting there is neuronal-glial
crosstalk with factors released from the stressed dopamine neurons
available to signal local glia causing a mild inflammatory response
that is not due to a direct glial-synuclein interaction (middle). As α-
synuclein continues to misfold into fibrils (far right and red arrow) and
oxidative stress is enhanced in the local microenvironment, more
microglia become activated in a robust proinflammatory pathway (blue
arrow) leading to increased dopamine neuron dysfunction (gray ar-
row). Similar to Panel (c.), at this point the antioxidant response cannot
suppress the ongoing glial activation
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receptors is only increased in the species of α-synuclein that
leads to proinflammation (i.e., SYN not SYNDA). Mecha-
nistic studies are underway to test this hypothesis.
Third, we show that along with a robust classic proin-
flammatory activation of microglia by α-synuclein there is
also evidence that these glia are oxidatively stressed as
indicated by an increased production of NO and expression
of NOX1. Again the strength of these responses appears to
be dependent on α-synuclein structure/modification as
GPX1, PRDX1, GSTA2, NQO1, HMOX1, GSS, GSR and
ABCC1 expression changes were all increased in misfolded
SYN-treated cells above the SYNDA-treated glia. For exam-
ple, SYNDA-treated microglia only increased the expression
of glutathione-S-transferase (GSTA) 60-fold while the re-
sponse to misfolded SYN was a 500-fold increase in gene
expression. However, we did observe that SYNDA altered
microglial morphology and ARE-driven hPLAP activity and
increased the expression of Nrf2-directed antioxidant
enzymes. Relevant to our observations, when microglia
derived from Nrf2-KO mice were exposed to α-synuclein,
the glia were unable to increase the expression of two
antioxidant enzymes (HO-1 and NQO1) and they took on
a more proinflammatory profile (Lastres-Becker et al. 2012)
demonstrating that Nrf2 can regulate microglial responses to
DAMPs. We also characterized the HO-1 response in micro-
glia since it is upregulated in response to α-synuclein and
dopamine [Figs. 8 & 9 and (Schmidt et al. 1999; Beraud et
al. 2011; Lastres-Becker et al. 2012)]. In addition to Nrf2
(Lastres-Becker et al. 2012), HO-1 expression is regulated
by other transcription factors, including AP1, NFĸB,
hypoxia-inducible factor 1 (HIF1) and stress response pro-
teins (Schipper et al. 2009) leading to a complex spatial and
temporal pattern of expression and function (Kraft et al.
2006, 2007; Chen et al. 2009; Rojo et al. 2010; Granado
et al. 2011; Koh et al. 2011; Lastres-Becker et al. 2012). For
example, HO-1 can be neuroprotective, promoting intracel-
lular degradation of soluble α-synuclein (Song et al. 2009)
and defending against hydrogen peroxide oxidative damage
as well as β-amyloid toxicity (Le et al. 1999; Wang et al.
2012). However, HO-1 is also able to facilitate bioenergetic
failure and in a toxicant model this leads to dopamine
neuron injury (Lee et al. 2006; Schipper et al. 2009). With
regard to PD, HO-1 is found surrounding the hallmark
proteinaceous PD inclusion, the Lewy body, and is in-
creased in PD brains where its function is still unclear
(Schipper et al. 1998). Here we show that HMOX1 expres-
sion is increased when human α-synuclein is overexpressed
in vivo and in cultured microglia exposed to SYN and
SYNDA. On the other hand, HO-1 protein levels were in-
creased and not substantially different from each other when
BV2 cells were treated with SYN, SYNDA or BufferDA. It
appears that the increase in HO-1 following SYN-treatment
is in response to oxidative stress emanating from glial
activation by misfolded α-synuclein but following SYNDA
or BufferDA increased HO-1 is a glial response to oxidized
dopamine. In both scenarios this robust HO-1 response
might be an attempt to promote homeostasis, which is
effective when microglia are not yet fully activated (i.e.,
BufferDA & SYNDA) but fails when glia are driven to a
robust classical activation state (i.e., misfolded SYN). Fur-
ther studies are necessary to determine the exact functional
state of these microglia. As such we are continuing to
investigate the exact structure of these misfolded α-
synuclein conformers, which should facilitate the develop-
ment of molecular tweezers (Prabhudesai et al. 2012) that
could target specific α-synuclein structures.
The other interesting target for a novel PD therapy is the
antioxidant transcription factor, Nrf2. PD is a progressive
disorder and increased age is the greatest risk factor for
developing this disease. In a mouse model of spontaneous
accelerated aging, Nrf2 expression and translocation to the
nucleus was decreased compared with normally aging
mice (Tomobe et al. 2012), suggesting that an age-
dependent decline in transcriptionally active Nrf2 could
add to the risk of developing diseases related to oxida-
tive stress such as PD. As mentioned above studies
using Nrf2/KO mice demonstrated that the loss of this
transcription factor makes neurons more vulnerable to
oxidative stress-related toxicants. Since Nrf2 upregulates
the expression of many antioxidant genes altering the
activity of this transcription factor would affect a wide
variety of antioxidant systems, which may represent a
stronger approach than targeting only one antioxidant
enzyme (reviewed in (Hybertson et al. 2011)). Nrf2
activators can be derived from plants for example, sulfor-
aphanes are from cruciferous vegetables and curcumin is
derived from the spice, turmeric. Mixtures of natural com-
pounds have also been formulated to produce low dose syn-
ergistic activation of Nrf2 (e.g., Protandim; LifeVantage
Corp; (Hybertson et al. 2011)). Synthetically produced
activators are also available such as tBHQ, synthetic triterpe-
noids, and dimethylfumarate (BG-12; Biogen Idec). These
Nrf2 activators are effective in both in vitro and in vivo
models of cancer, diabetes, inflammatory disorders and
neurodegenerative diseases (Calabrese et al. 2010; Hu et
al. 2010; Kundu and Surh 2010; Kwak and Kensler 2010;
Hybertson et al. 2011; Negi et al. 2011; Perumal and Khan
2012). In addition many of these compounds (e.g., sulfora-
phanes, BG-12 and curcumin) are being tested in human
clinical trials for a number of immune-related and neurologic
conditions including multiple sclerosis and Alzheimer’s dis-
ease ((Hybertson et al. 2011; Perumal and Khan 2012);
www.ClinicalTrials.gov). Since the regulation of Nrf2 ac-
tivity is dependent on the ability of this protein to
disengage from KEAP1 and translocate to the nucleus
and there is evidence of cross talk between this
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antioxidant response pathway and others (e.g., adipogenic,
ubiquitin, inflammatory) the development of small molecules
that mimic Nrf2 activity and/or weaken its interaction with
KEAP1 also represent a fertile area of pharmacologic explo-
ration (Wakabayashi et al. 2010).
In conclusion, we have reviewed the literature, which
supports the idea that microglial activation is important in
PD progression and have shown that the PD-related protein,
α-synuclein, incites an increase in antioxidant response
enzyme expression in vivo and in cultured microglia. Fur-
thermore, we demonstrated that the specific structure of
misfolded α-synuclein dictates the glial activation pattern
and antioxidant responses. The development of small mol-
ecules that either prevent the formation of or disrupt the
structure of the proinflammatory form of α-synuclein in
combination with natural or synthetic Nrf2 activators will
enhance the armamentarium to combat PD.
Acknowledgments We thank Mr. Eric Yehling and Mr. Brett Brown
for expert technical assistance. This work was supported by NIEHS
R01ES014470 (KMZ); The Parkinson’s & Movement Disorder Foun-
dation Award (KMZ); NINDS 2T32NS041218 (DB); ARRA NINDS
R01NS057257 (HJF).
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or L-DOPA-
induced neurotoxicity: the role of dopamine quinone formation
and tyrosinase in a model of Parkinson’s disease. Neurotox Res 5
(3):165–176
Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski
JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy
bodies of sporadic Parkinson’s disease and dementia with Lewy
bodies. Am J Pathol 152(4):879–884
Banati RB (2002) Visualising microglial activation in vivo. GLIA 40
(2):206–217
Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza
YPM, Fernandez-Barreiro A, Hirsch EC, Herrero MT (2004)
Evidence of active microglia in substantia nigra pars compacta
of parkinsonian monkeys 1 year after MPTP exposure. GLIA 46
(4):402–409
Bartels AL, Leenders KL (2007) Neuroinflammation in the pathophys-
iology of Parkinson’s disease: evidence from animal models to
human in vivo studies with [11C]-PK11195 PET. Mov Disord 22
(13):1852–1856
Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA,
Leenders KL (2010) [11C]-PK11195 PET: quantification of neu-
roinflammation and a monitor of anti-inflammatory treatment in
Parkinson’s disease? Parkinsonism Relat Disord 16(1):57–59
Bast A, Erttmann SF, Walther R, Steinmetz I (2010) Influence of iNOS
and COX on peroxiredoxin gene expression in primary macro-
phages. Free Radic Biol Med 49(12):1881–1891
Beal MF (2011) Neuroprotective effects of creatine. Amino Acids 40
(5):1305–1313
Beraud D, Maguire-Zeiss KA (2012) Misfolded alpha-synuclein and
Toll-like receptors: therapeutic targets for Parkinson’s disease.
Parkinsonism Relat Disord 18(Suppl 1):S17–S20
Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K,
Chasovskikh S, Mhyre TR, Maguire-Zeiss KA (2011) alpha-
Synuclein Alters Toll-Like Receptor Expression. Front Neurosci 5:80
Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F (1990) Immor-
talization of murine microglial cells by a v-raf/v-myc carrying
retrovirus. J Neuroimmunol 27(2–3):229–237
Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxic-
ity: uncovering the molecular mechanisms. Nat Rev Neurosci 8
(1):57–69
Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular
pathways to neurodegeneration. Nat Med 10(Suppl):S2–S9
Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N,
Chalimoniuk M, Stepien A (2008) Serum interleukin (IL-2, IL-10,
IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevat-
ed in patients with atypical and idiopathic parkinsonism. Neurosci
Lett 441(2):158–162
Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson
MP (2010) Cellular stress responses, the hormesis paradigm, and
vitagenes: novel targets for therapeutic intervention in neurodegen-
erative disorders. Antioxid Redox Signal 13(11):1763–1811
Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X,
Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M,
Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A
(2004) Alpha-synuclein locus duplication as a cause of fa-
milial Parkinson’s disease. Lancet 364(9440):1167–1169
Chen GY, Nunez G (2010) Sterile inflammation: sensing and reacting
to damage. Nat Rev Immunol 10(12):826–837
Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW,
Johnson JA (2009) Nrf2-mediated neuroprotection in the MPTP
mouse model of Parkinson’s disease: Critical role for the astro-
cyte. Proc Natl Acad Sci U S A 106(8):2933–2938
Cheret C, Gervais A, Lelli A, Colin C, Amar L, Ravassard P, Mallet J,
Cumano A, Krause KH, Mallat M (2008) Neurotoxic activation of
microglia is promoted by a nox1-dependent NADPH oxidase. J
Neurosci 28(46):12039–12051
Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam
SR (2012) A progressive mouse model of Parkinson’s disease: the
Thy1-aSyn (“Line 61”) mice. Neurotherapeutics 9(2):297–314
Chowdhury I, Mo Y, Gao L, Kazi A, Fisher AB, Feinstein SI (2009)
Oxidant stress stimulates expression of the human peroxiredoxin
6 gene by a transcriptional mechanism involving an antioxidant
response element. Free Radic Biol Med 46(2):146–153
Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O
(2002) Neuroinflammation of the nigrostriatal pathway during
progressive 6-OHDA dopamine degeneration in rats monitored
by immunohistochemistry and PET imaging. Eur J Neurosci 15
(6):991–998
Colapinto M, Mila S, Giraudo S, Stefanazzi P, Molteni M, Rossetti C,
Bergamasco B, Lopiano L, Fasano M (2006) alpha-Synuclein
protects SH-SY5Y cells from dopamine toxicity. Biochem Bio-
phys Res Commun 349(4):1294–1300
Colton CA, Wilcock DM (2010) Assessing activation states in micro-
glia. CNS Neurol Disord Drug Targets 9(2):174–191
Colton CA, Chernyshev ON, Gilbert DL, Vitek MP (2000) Microglial
contribution to oxidative stress in Alzheimer’s disease. Ann N Y
Acad Sci 899:292–307
Combs CK, Karlo JC, Kao SC, Landreth GE (2001) beta-Amyloid
stimulation of microglia and monocytes results in TNFalpha-
J Neuroimmune Pharmacol (2013) 8:94–117 113
dependent expression of inducible nitric oxide synthase and neu-
ronal apoptosis. J Neurosci 21(4):1179–1188
Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic
Stabilization of the alpha -Synuclein Protofibril by a Dopamine-
alpha -Synuclein Adduct. Science 294(5545):1346–1349
Cookson MR, van der Brug M (2008) Cell systems and the toxic
mechanism(s) of alpha-synuclein. Exp Neurol 209(1):5–11
Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski
A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) induced Parkinson’s disease mice model. Neu-
rodegeneration 5(2):137–143
Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A,
Kretzschmar H, Hengerer B, Kostka M (2007) Different species
of alpha-synuclein oligomers induce calcium influx and seeding. J
Neurosci 27(34):9220–9232
Dawson T, Mandir A, Lee M (2002) Animal models of PD: pieces of
the same puzzle? Neuron 35(2):219–222
Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del
Rey A, Pitossi FJ, Oertel WH (2003) Microglial activation with
atypical proinflammatory cytokine expression in a rat model of
Parkinson’s disease. Eur J Neurosci 18(10):2731–2742
Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L,
Spencer B, Masliah E, Lee SJ (2009) Inclusion formation and
neuronal cell death through neuron-to-neuron transmission of
alpha-synuclein. Proc Natl Acad Sci U S A 106(31):13010–13015
Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheertha-
varada HK (2008) Mitochondrial import and accumulation of
alpha-synuclein impair complex I in human dopaminergic neuro-
nal cultures and Parkinson disease brain. J Biol Chem 283
(14):9089–9100
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway
RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf
A, Tanner CM (2007) Projected number of people with Parkinson
disease in the most populous nations, 2005 through 2030. Neu-
rology 68(5):384–386
Duewell P, KonoH, Rayner KJ, Sirois CM,Vladimer G, Bauernfeind FG,
Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E,
Fitzgerald KA, Rock KL,Moore KJ,Wright SD, Hornung V, Latz E
(2010) NLRP3 inflammasomes are required for atherogenesis and
activated by cholesterol crystals. Nature 464(7293):1357–1361
Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham
GW, Wang L, Zuchner S, Konidari I, Wang G, Singer C, Nahab F,
Scott B, Stajich JM, Pericak-Vance M, Haines J, Vance JM,
Martin ER (2010) Genome-wide association study confirms SNPs
in SNCA and the MAPT region as common risk factors for
Parkinson disease. Ann Hum Genet 74(2):97–109
El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M,
Freeman MW, Luster AD (2003) CD36 mediates the innate host
response to beta-amyloid. J Exp Med 197(12):1657–1666
El-Agnaf OM, Irvine GB (2000) Review: formation and properties of
amyloid-like fibrils derived from alpha-synuclein and related
proteins. J Struct Biol 130(2–3):300–309
El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R,
Bianchi E, Pessi A, Neill D, Wallace A (1998) Aggregates
from mutant and wild-type alpha-synuclein proteins and NAC
peptide induce apoptotic cell death in human neuroblastoma cells by
formation of beta-sheet and amyloid-like filaments. FEBS Lett 440
(1–2):71–75
El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ,
Court JA, Schlossmacher MG, Allsop D (2006) Detection of
oligomeric forms of alpha-synuclein protein in human plasma as
a potential biomarker for Parkinson’s disease. FASEB J 20
(3):419–425
Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D (2002) Mutant
and wild-type alpha-synuclein interact with mitochondrial cyto-
chrome C oxidase. J Mol Neurosci 18(3):229–238
Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD,
Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K (2010a) Cell-
produced alpha-synuclein is secreted in a calcium-dependent
manner by exosomes and impacts neuronal survival. J Neurosci
30(20):6838–6851
Emmanouilidou E, Stefanis L, Vekrellis K (2010b) Cell-produced
alpha-synuclein oligomers are targeted to, and impair, the 26S
proteasome. Neurobiol Aging 31(6):953–968
Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s
disease. Nature 404(6776):394–398
Feng LR, Federoff HJ, Vicini S, Maguire-Zeiss KA (2010) Alpha-
synuclein mediates alterations in membrane conductance: a po-
tential role for alpha-synuclein oligomers in cell vulnerability. Eur
J Neurosci 32(1):10–17
Galvin JE (2006) Interaction of alpha-synuclein and dopamine metab-
olites in the pathogenesis of Parkinson’s disease: a case for the
selective vulnerability of the substantia nigra. Acta Neuropathol
112(2):115–126
Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A,
Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imag-
ing of microglial activation with [11C](R)-PK11195 PET in idio-
pathic Parkinson’s disease. Neurobiol Dis 21(2):404–412
Giasson BI, Lee VM (2003) Are ubiquitination pathways central to
Parkinson’s disease? Cell 114(1):1–8
Giasson BI, Uryu K, Trojanowski JQ, Lee VM (1999) Mutant and wild
type human alpha-synucleins assemble into elongated filaments
with distinct morphologies in vitro. J Biol Chem 274(12):7619–
7622
Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI,
Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative
damage linked to neurodegeneration by selective alpha-
synuclein nitration in synucleinopathy lesions. Science 290
(5493):985–989
Giorgi FS, Bandettini di Poggio, A, Battaglia G, Pellegrini A, Murri L,
Ruggieri S, Paparelli A and Fornai F (2006) A short overview
on the role of alpha-synuclein and proteasome in experimen-
tal models of Parkinson’s disease. J Neural Transm Suppl(70):
105–109
Granado N, Lastres-Becker I, Ares-Santos S, Oliva I, Martin E, Cuadrado
A and Moratalla R (2011) Nrf2 deficiency potentiates
methamphetamine-induced dopaminergic axonal damage and glio-
sis in the striatum. Glia
Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E,
Schumacker PT and Surmeier DJ (2010) Oxidant stress evoked
by pacemaking in dopaminergic neurons is attenuated by DJ-1.
Nature
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel
T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The
NALP3 inflammasome is involved in the innate immune response
to amyloid-beta. Nat Immunol 9(8):857–865
Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J,
Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI,
Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J,
Factor SA, Payami H (2010) Common genetic variation in the
HLA region is associated with late-onset sporadic Parkinson’s
disease. Nat Genet 42(9):781–785
Hardy J (2010) Genetic analysis of pathways to Parkinson disease.
Neuron 68(2):201–206
Harry GJ, Kraft AD (2012) Microglia in the developing brain: a potential
target with lifetime effects. Neurotoxicology 33(2):191–206
Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E
(1999) Oxidative stress induces amyloid-like aggregate formation of
NACP/alpha- synuclein in vitro. Neuroreport 10(4):717–721
He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation
and protects nigral cells after 6-hydroxydopamine injection into
mouse striatum. Brain Research 909(1–2):187–193
114 J Neuroimmune Pharmacol (2013) 8:94–117
Henn A, Lund S, Hedtjarn M, Schrattenholz A, Porzgen P, Leist M
(2009) The suitability of BV2 cells as alternative model system
for primary microglia cultures or for animal experiments examin-
ing brain inflammation. ALTEX 26(2):83–94
Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA (2008)
Differential migration, LPS-induced cytokine, chemokine, and
NO expression in immortalized BV-2 and HAPI cell lines and
primary microglial cultures. J Neurochem 107(2):557–569
Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong
J, Takenouchi T, Hashimoto M, Masliah E (2000) alpha-synuclein
promotes mitochondrial deficit and oxidative stress. Am J Pathol
157(2):401–410
Hu S, Chao CC, Khanna KV, Gekker G, Peterson PK, Molitor TW
(1996) Cytokine and free radical production by porcine microglia.
Clin Immunol Immunopathol 78(1):93–96
Hu R, Saw CL, Yu R, Kong AN (2010) Regulation of NF-E2-related
factor 2 signaling for cancer chemoprevention: antioxidant coupled
with antiinflammatory. Antioxid Redox Signal 13(11):1679–1698
Hybertson BM, Gao B, Bose SK, McCord JM (2011) Oxidative stress
in health and disease: the therapeutic potential of Nrf2 activation.
Mol Aspects Med 32(4–6):234–246
Ischiropoulos H (2003) Oxidative modifications of alpha-synuclein.
Ann N YAcad Sci 991:93–100
Jana M, Palencia CA, Pahan K (2008) Fibrillar amyloid-beta peptides
activate microglia via TLR2: implications for Alzheimer’s dis-
ease. J Immunol 181(10):7254–7262
Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ (2010) Non-classical
exocytosis of alpha-synuclein is sensitive to folding states and
promoted under stress conditions. J Neurochem 113(5):1263–1274
Johnson DA, Andrews GK, Xu W, Johnson JA (2002) Activation of
the antioxidant response element in primary cortical neuronal
cultures derived from transgenic reporter mice. J Neurochem 81
(6):1233–1241
Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas
MR, Chen PC (2008) The Nrf2-ARE pathway: an indicator and
modulator of oxidative stress in neurodegeneration. Ann N Y
Acad Sci 1147:61–69
Kim YS, Joh TH (2006) Microglia, major player in the brain inflam-
mation: their roles in the pathogenesis of Parkinson’s disease. Exp
Mol Med 38(4):333–347
Kim YH, Lussier S, Rane A, Choi SW, Andersen JK (2011a) Inducible
dopaminergic glutathione depletion in an alpha-synuclein trans-
genic mouse model results in age-related olfactory dysfunction.
Neuroscience 172:379–386
Kim YM, Pae HO, Park JE, Lee YC, Woo JM, Kim NH, Choi YK, Lee
BS, Kim SR, Chung HT (2011b) Heme oxygenase in the regula-
tion of vascular biology: from molecular mechanisms to thera-
peutic opportunities. Antioxid Redox Signal 14(1):137–167
Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka
N, Mandel RJ, Bjorklund A (2002) Parkinson-like neurodegener-
ation induced by targeted overexpression of alpha-synuclein in
the nigrostriatal system. J Neurosci 22(7):2780–2791
Kitamura Y, Furukawa M, Matsuoka Y, Tooyama I, Kimura H,
Nomura Y, Taniguchi T (1998a) In vitro and in vivo induction
of heme oxygenase-1 in rat glial cells: possible involvement of
nitric oxide production from inducible nitric oxide synthase.
GLIA 22(2):138–148
Kitamura Y, Matsuoka Y, Nomura Y, Taniguchi T (1998b) Induction of
inducible nitric oxide synthase and heme oxygenase-1 in rat glial
cells. Life Sci 62(17–18):1717–1721
Koenigsknecht J, Landreth G (2004) Microglial phagocytosis of fibril-
lar beta-amyloid through a beta1 integrin-dependent mechanism. J
Neurosci 24(44):9838–9846
Koh K, Kim J, Jang YJ, Yoon K, Cha Y, Lee HJ (2011) Transcription
factor Nrf2 suppresses LPS-induced hyperactivation of BV-2
microglial cells. J Neuroimmunol 233(1–2):160–167
Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkow-
ski A, Czlonkowska A (1998) Microglial and astrocytic involve-
ment in a murine model of Parkinson’s disease induced by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immuno-
pharmacology 39(3):167–180
Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2-related
factor 2-dependent antioxidant response element activation by
tert-butylhydroquinone and sulforaphane occurring preferentially
in astrocytes conditions neurons against oxidative insult. J Neuro-
sci 24(5):1101–1112
Kraft AD, Lee JM, Johnson DA, Kan YW, Johnson JA (2006) Neuronal
sensitivity to kainic acid is dependent on the Nrf2-mediated actions
of the antioxidant response element. J Neurochem 98(6):1852–1865
Kraft AD, Resch JM, Johnson DA, Johnson JA (2007) Activation of
the Nrf2-ARE pathway in muscle and spinal cord during ALS-
like pathology in mice expressing mutant SOD1. Exp Neurol 207
(1):107–117
Kundu JK, Surh YJ (2010) Nrf2-Keap1 signaling as a potential target
for chemoprevention of inflammation-associated carcinogenesis.
Pharm Res 27(6):999–1013
Kwak MK, Kensler TW (2010) Targeting NRF2 signaling for cancer
chemoprevention. Toxicol Appl Pharmacol 244(1):66–76
Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rabano A,
Kirik D and Cuadrado A (2012) alpha-Synuclein expression and
Nrf2 deficiency cooperate to aggravate protein aggregation, neu-
ronal death and inflammation in early-stage Parkinson’s disease.
Hum Mol Genet
Le WD, Xie WJ, Appel SH (1999) Protective role of heme oxygenase-
1 in oxidative stress-induced neuronal injury. J Neurosci Res 56
(6):652–658
Lee SJ, Lee S (2002) Toll-like receptors and inflammation in the CNS.
Curr Drug Targets Inflamm Allergy 1(2):181–191
Lee M, Hyun D, Halliwell B, Jenner P (2001) Effect of the over-
expression of wild-type or mutant alpha-synuclein on cell suscep-
tibility to insult. J Neurochem 76(4):998–1009
Lee HJ, Patel S, Lee SJ (2005) Intravesicular localization and exocy-
tosis of alpha-synuclein and its aggregates. J Neurosci 25
(25):6016–6024
Lee DW, Gelein RM, Opanashuk LA (2006) Heme-oxygenase-1 pro-
motes polychlorinated biphenyl mixture aroclor 1254-induced
oxidative stress and dopaminergic cell injury. Toxicol Sci 90
(1):159–167
Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK, Junn E,
Kim HS (2010a) Alpha-synuclein activates microglia by inducing
the expressions of matrix metalloproteinases and the subsequent
activation of protease-activated receptor-1. J Immunol 185
(1):615–623
Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah
E, Lee SJ (2010b) Direct transfer of alpha-synuclein from neuron
to astroglia causes inflammatory responses in synucleinopathies. J
Biol Chem 285(12):9262–9272
Lesage S, Brice A (2009) Parkinson’s disease: from monogenic forms to
genetic susceptibility factors. Hum Mol Genet 18(R1):R48–R59
Leung L, Kwong M, Hou S, Lee C, Chan JY (2003) Deficiency of the
Nrf1 and Nrf2 transcription factors results in early embryonic
lethality and severe oxidative stress. J Biol Chem 278(48):48021–
48029
Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB,
Jensen PH (2004) Proteasomal inhibition by alpha-synuclein fil-
aments and oligomers. J Biol Chem 279(13):12924–12934
Liu B (2006) Modulation of microglial pro-inflammatory and neuro-
toxic activity for the treatment of Parkinson’s disease. AAPS J 8
(3):E606–E621
Maguire-Zeiss KA, Short DW, Federoff HJ (2005) Synuclein, dopa-
mine and oxidative stress: co-conspirators in Parkinson’s disease?
Brain Res Mol Brain Res 134(1):18–23
J Neuroimmune Pharmacol (2013) 8:94–117 115
Maguire-Zeiss KA, Wang CI, Yehling E, Sullivan MA, Short DW, Su
X, Gouzer G, Henricksen LA, Wuertzer CA, Federoff HJ (2006)
Identification of human alpha-synuclein specific single chain anti-
bodies. Biochem Biophys Res Commun 349(4):1198–1205
Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA,
Price DL, Lee MK (2006) Parkinson’s disease alpha-synuclein
transgenic mice develop neuronal mitochondrial degeneration and
cell death. J Neurosci 26(1):41–50
Martin I, Dawson VL, Dawson TM (2011) Recent advances in the
genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet
12:301–325
Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P (2012)
Pharmacological manipulation of peroxisome proliferator-
activated receptor gamma (PPARgamma) reveals a role for anti-
oxidant protection in a model of Parkinson’s disease. Exp Neurol
235(2):528–538
Martinez-Banaclocha MA (2012) N-acetyl-cysteine in the treatment of
Parkinson’s disease. What are we waiting for? Med Hypotheses
79(1):8–12
Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J,
Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer
W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo
AM (2008) Dopamine-modified alpha-synuclein blocks chaperone-
mediated autophagy. J Clin Invest 118(2):777–788
Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M,
Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss
and inclusion body formation in alpha-synuclein mice: implica-
tions for neurodegenerative disorders. Science 287(5456):1265–
1269
Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois
J, Yu X, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J,
Duff K, Przedborski S, Di Monte DA (2001) Lack of nigral pathol-
ogy in transgenic mice expressing human alpha- synuclein driven by
the tyrosine hydroxylase promoter. Neurobiol Dis 8(3):535–539
McGeer PL, Itagaki S, Boyes BE,McGeer EG (1988) Reactive microglia
are positive for HLA-DR in the substantia nigra of Parkinson’s and
Alzheimer’s disease brains. Neurology 38(8):1285–1291
Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC Jr,
Lau YS (2002) Lysosomal malfunction accompanies alpha-
synuclein aggregation in a progressive mouse model of Parkin-
son’s disease. Brain Res 956(1):156–165
Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K,
Cookson MR, Singleton AB (2004) Alpha-synuclein in blood
and brain from familial Parkinson disease with SNCA locus
triplication. Neurology 62(10):1835–1838
Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxidative and
inflammatory pathways in Parkinson’s disease. Neurochem Res
34(1):55–65
Mollenhauer B, El-AgnafOMA,MarcusK, Trenkwalder C, Schlossmacher
MG (2010) Quantification of α-synuclein in cerebrospinal fluid as a
biomarker candidate: review of the literature and considerations for
future studies. Biomarkers in Medicine 4(5):683–699
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F,
Trenkwalder C, Schlossmacher MG (2011) alpha-Synuclein
and tau concentrations in cerebrospinal fluid of patients pre-
senting with parkinsonism: a cohort study. Lancet Neurol 10
(3):230–240
Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz
Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009)
Interplay between cytosolic dopamine, calcium, and alpha-
synuclein causes selective death of substantia nigra neurons.
Neuron 62(2):218–229
Muzio M, Polentarutti N, Bosisio D, Prahladan MK, Mantovani A
(2000) Toll-like receptors: a growing family of immune receptors
that are differentially expressed and regulated by different leuko-
cytes. J Leukoc Biol 67(4):450–456
Negi G, Kumar A, Joshi RP, Sharma SS (2011) Oxidative stress
and Nrf2 in the pathophysiology of diabetic neuropathy: old
perspective with a new angle. Biochem Biophys Res Commun 408
(1):1–5
Noguchi-ShinoharaM, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa
M, El-Agnaf OM, Yamada M (2009) CSF alpha-synuclein levels in
dementia with Lewy bodies and Alzheimer’s disease. Brain Res
1251:1–6
OhtsujiM, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD, Yamamoto
M (2008) Nrf1 and Nrf2 play distinct roles in activation of antiox-
idant response element-dependent genes. J Biol Chem 283
(48):33554–33562
Ono K, Yamada M (2006) Antioxidant compounds have potent anti-
fibrillogenic and fibril-destabilizing effects for alpha-synuclein
fibrils in vitro. J Neurochem 97(1):105–115
Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu
T, Torizuka T (2005) Microglial activation and dopamine ter-
minal loss in early Parkinson’s disease. Ann Neurol 57(2):168–
175
Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroinflamma-
tion in the living brain of Parkinson’s disease. Parkinsonism Relat
Disord 15(Suppl 3):S200–S204
Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P (2008)
Mitochondrial association of alpha-synuclein causes oxidative
stress. Cell Mol Life Sci 65(7–8):1272–1284
Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P (2009)
Alpha-synuclein overexpression and aggregation exacerbates im-
pairment of mitochondrial functions by augmenting oxidative
stress in human neuroblastoma cells. Int J Biochem Cell Biol 41
(10):2015–2024
Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM,
Trojanowski JQ, Lee VM, Ischiropoulos H (2001) Induction of
alpha-synuclein aggregation by intracellular nitrative insult. J
Neurosci 21(20):8053–8061
Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB
(2007) Aggregated alpha-synuclein mediates dopaminergic neu-
rotoxicity in vivo. J Neurosci 27(12):3338–3346
Perumal J, Khan O (2012) Emerging disease-modifying therapies in
multiple sclerosis. Curr Treat Options Neurol 14(3):256–263
Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG,
Lakshmanan R, Ivanova MI, Loo JA, Klarner FG, Schrader
T, Stahl M, Bitan G, Bronstein JM (2012) A Novel “Molec-
ular Tweezer” Inhibitor of alpha-Synuclein Neurotoxicity in
Vitro and in Vivo. Neurotherapeutics 9(2):464–476
Qian L, Block ML, Wei SJ, Lin CF, Reece J, Pang H, Wilson B, Hong
JS, Flood PM (2006a) Interleukin-10 protects lipopolysaccharide-
induced neurotoxicity in primary midbrain cultures by inhibiting
the function of NADPH oxidase. J Pharmacol Exp Ther 319
(1):44–52
Qian L, Hong JS and Flood PM (2006b) Role of microglia in
inflammation-mediated degeneration of dopaminergic neurons:
neuroprotective effect of interleukin 10. J Neural Transm Suppl
(70): 367–371.
Reynolds AD, Kadiu I, Garg SK, Glanzer JG, Nordgren T, Ciborowski
P, Banerjee R, Gendelman HE (2008) Nitrated Alpha-Synuclein
and Microglial Neuroregulatory Activities. J Neuroimmune Phar-
macol 3(2):59–74
Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C,
Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ
(2002) Behavioral and neurochemical effects of wild-type
and mutated human alpha-synuclein in transgenic mice. Exp
Neurol 175(1):35–48
Rodrigues e Silva AM, Geldsetzer F, Holdorff B, Kielhorn FW,
Balzer-Geldsetzer M, Oertel WH, Hurtig H, Dodel R (2010)
Who was the man who discovered the “Lewy bodies”? Mov
Disord 25(12):1765–1773
116 J Neuroimmune Pharmacol (2013) 8:94–117
Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML,
Yamamoto M, Cuadrado A (2010) Nrf2 regulates microglial
dynamics and neuroinflammation in experimental Parkinson’s
disease. GLIA 58(5):588–598
Sawada M, Imamura K and Nagatsu T (2006) Role of cytokines in
inflammatory process in Parkinson’s disease. J Neural Transm
Suppl(70): 373–381
Schipper HM, Liberman A, Stopa EG (1998) Neural heme oxygenase-
1 expression in idiopathic Parkinson’s disease. Exp Neurol 150
(1):60–68
Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D (2009)
Heme oxygenase-1 and neurodegeneration: expanding frontiers of
engagement. J Neurochem 110(2):469–485
Schmidt J, Mertz K, Morgan JI (1999) Regulation of heme oxygenase-
1 expression by dopamine in cultured C6 glioma and primary
astrocytes. Brain Res Mol Brain Res 73(1–2):50–59
Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER,
Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB,
Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J,
Goldstein D, Zhang J (2011) Cerebrospinal fluid biomarkers for
Parkinson disease diagnosis and progression. Ann Neurol 69
(3):570–580
Shlyakhtenko LS, Potaman VN, Sinden RR, Gall AA, Lyubchenko YL
(2000) Structure and dynamics of three-way DNA junctions: atomic
force microscopy studies. Nucleic Acids Res 28(18):3472–3477
Shlyakhtenko LS, Gall AA, Filonov A, Cerovac Z, Lushnikov A,
Lyubchenko YL (2003) Silatrane-based surface chemistry for
immobilization of DNA, protein-DNA complexes and other bio-
logical materials. Ultramicroscopy 97(1–4):279–287
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus
J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S,
Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR,
Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-
Hardy K (2003) alpha-Synuclein locus triplication causes Parkin-
son’s disease. Science 302(5646):841
Singleton A, Gwinn-Hardy K, Sharabi Y, Li ST, Holmes C, Dendi R,
Hardy J, Crawley A, Goldstein DS (2004) Association between
cardiac denervation and parkinsonism caused by alpha-synuclein
gene triplication. Brain 127(Pt 4):768–772
Song W, Patel A, Qureshi HY, Han D, Schipper HM, Paudel HK
(2009) The Parkinson disease-associated A30P mutation stabil-
izes alpha-synuclein against proteasomal degradation triggered by
heme oxygenase-1 over-expression in human neuroblastoma
cells. J Neurochem 110(2):719–733
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R,
Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388
(6645):839–840
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M
(1998) alpha-Synuclein in filamentous inclusions of Lewy bodies
from Parkinson’s disease and dementia with lewy bodies. Proc
Natl Acad Sci U S A 95(11):6469–6473
Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A,
Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El
Khoury J, Golenbock DT, Moore KJ (2010) CD36 ligands pro-
mote sterile inflammation through assembly of a Toll-like recep-
tor 4 and 6 heterodimer. Nat Immunol 11(2):155–161
Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff
HJ (2008) Synuclein activates microglia in a model of Parkinson’s
disease. Neurobiol Aging 29(11):1690–1701
Su X, Federoff HJ, Maguire-Zeiss KA (2009) Mutant alpha-Synuclein
Overexpression Mediates Early Proinflammatory Activity. Neuro-
tox Res 16(3):238–254
Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2010)
What causes the death of dopaminergic neurons in Parkinson’s
disease? Prog Brain Res 183:59–77
Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE,
Sawa A, Dawson VL, Dawson TM, Ross CA (2001) Inducible
expression of mutant alpha-synuclein decreases proteasome ac-
tivity and increases sensitivity to mitochondria-dependent apopto-
sis. Hum Mol Genet 10(9):919–926
Tanaka S, Ide M, Shibutani T, Ohtaki H, Numazawa S, Shioda S,
Yoshida T (2006) Lipopolysaccharide-induced microglial activa-
tion induces learning and memory deficits without neuronal cell
death in rats. J Neurosci Res 83(4):557–566
Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted over-
expression of human alpha-synuclein triggers microglial activa-
tion and an adaptive immune response in a mouse model of
Parkinson disease. J Neuropathol Exp Neurol 67(12):1149–1158
Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T,
Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM (2010) De-
tection of elevated levels of alpha-synuclein oligomers in CSF from
patients with Parkinson disease. Neurology 75(20):1766–1772
Tomobe K, Shinozuka T, Kuroiwa M, Nomura Y (2012) Age-related
changes of Nrf2 and phosphorylated GSK-3beta in a mouse model
of accelerated aging (SAMP8). Arch Gerontol Geriatr 54(2):e1–e7
Trinh K, Moore K, Wes PD, Muchowski PJ, Dey J, Andrews L,
Pallanck LJ (2008) Induction of the phase II detoxification path-
way suppresses neuron loss in Drosophila models of Parkinson’s
disease. J Neurosci 28(2):465–472
Uversky VN (2007) Neuropathology, biochemistry, and biophysics of
alpha-synuclein aggregation. J Neurochem 103(1):17–37
Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ (2001a) Stabilization of
partially folded conformation during alpha -synuclein oligomeri-
zation in both purified and cytosolic preparations. J Biol Chem
276(47):43495–43498
Uversky VN, Li J, Fink AL (2001b) Evidence for a partially folded
intermediate in alpha-synuclein fibril formation. J Biol Chem 276
(14):10737–10744
Uversky VN, Li J, Fink AL (2001c) Metal-triggered Structural Trans-
formations, Aggregation, and Fibrillation of Human alpha -
Synuclein. A possible molecular link between Parkinson’s disease
and heavy metal exposure. J Biol Chem 276(47):44284–44296
Uversky VN, Li J, Fink AL (2001d) Pesticides directly accelerate the
rate of alpha-synuclein fibril formation: a possible factor in Par-
kinson’s disease. FEBS Lett 500(3):105–108
Uversky VN, Li J, Souillac P, Millett IS, Doniach S, Jakes R, Goedert
M, Fink AL (2002) Biophysical properties of the synucleins and
their propensities to fibrillate: inhibition of alpha-synuclein as-
sembly by beta- and gamma-synucleins. J Biol Chem 277
(14):11970–11978
Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW (2010)
When NRF2 talks, who’s listening? Antioxid Redox Signal 13
(11):1649–1663
Wang HQ, Xu YX, Zhu CQ (2012) Upregulation of heme oxygenase-1
by acteoside through ERK and PI3 K/Akt pathway confer neuro-
protection against beta-amyloid-induced neurotoxicity. Neurotox
Res 21(4):368–378
Wu XF, Block ML, Zhang W, Qin L, Wilson B, Zhang WQ, Veronesi B,
Hong JS (2005) The role of microglia in paraquat-induced dopami-
nergic neurotoxicity. Antioxid Redox Signal 7(5–6):654–661
Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B,
Zhou Y, Hong JS, Zhang J (2005) Aggregated alpha-synuclein
activates microglia: a process leading to disease progression in
Parkinson’s disease. FASEB J 19(6):533–542
J Neuroimmune Pharmacol (2013) 8:94–117 117
